filings.toolsItem 1. Financial Statements
141K characters. Original on sec.gov · Markdown
Item 1. Financial Statements
THE COCA-COLA COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF INCOME
(In millions except per share data)
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | ||||||||||||||
| Net Operating Revenues | $ | 12,535 | $ | 12,363 | $ | 23,664 | $ | 23,663 | |||||||||
| Cost of goods sold | 4,714 | 4,812 | 8,877 | 9,047 | |||||||||||||
| Gross Profit | 7,821 | 7,551 | 14,787 | 14,616 | |||||||||||||
| Selling, general and administrative expenses | 3,470 | 3,549 | 6,704 | 6,900 | |||||||||||||
| Other operating charges | 71 | 1,370 | 144 | 2,943 | |||||||||||||
| Operating Income | 4,280 | 2,632 | 7,939 | 4,773 | |||||||||||||
| Interest income | 188 | 275 | 368 | 521 | |||||||||||||
| Interest expense | 445 | 418 | 832 | 800 | |||||||||||||
| Equity income (loss) — net | 561 | 537 | 912 | 891 | |||||||||||||
| Other income (loss) — net | 212 | 2 | 466 | 1,515 | |||||||||||||
| Income Before Income Taxes | 4,796 | 3,028 | 8,853 | 6,900 | |||||||||||||
| Income taxes | 993 | 627 | 1,715 | 1,314 | |||||||||||||
| Consolidated Net Income | 3,803 | 2,401 | 7,138 | 5,586 | |||||||||||||
| Less: Net income (loss) attributable to noncontrolling interests | (7) | (10) | (2) | (2) | |||||||||||||
| Net Income Attributable to Shareowners of The Coca-Cola Company | $ | 3,810 | $ | 2,411 | $ | 7,140 | $ | 5,588 | |||||||||
| Basic Net Income Per Share****1 | $ | 0.89 | $ | 0.56 | $ | 1.66 | $ | 1.30 | |||||||||
| Diluted Net Income Per Share****1 | $ | 0.88 | $ | 0.56 | $ | 1.65 | $ | 1.29 | |||||||||
| Average Shares Outstanding — Basic | 4,304 | 4,309 | 4,303 | 4,309 | |||||||||||||
| Effect of dilutive securities | 11 | 10 | 11 | 12 | |||||||||||||
| Average Shares Outstanding — Diluted | 4,315 | 4,319 | 4,314 | 4,321 |
1 Calculated based on net income attributable to shareowners of The Coca-Cola Company.
Refer to Notes to Consolidated Financial Statements.
THE COCA-COLA COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME
(In millions)
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | ||||||||||||||
| Consolidated Net Income | $ | 3,803 | $ | 2,401 | $ | 7,138 | $ | 5,586 | |||||||||
| Other Comprehensive Income: | |||||||||||||||||
| Net foreign currency translation adjustments | 1,103 | (1,014) | 1,722 | (1,317) | |||||||||||||
| Net gains (losses) on derivatives | (344) | 118 | (601) | 167 | |||||||||||||
| Net change in unrealized gains (losses) on available-for-sale debt securities | 10 | (27) | 23 | (22) | |||||||||||||
| Net change in pension and other postretirement benefit liabilities | 1 | 27 | 20 | 23 | |||||||||||||
| Total Comprehensive Income | 4,573 | 1,505 | 8,302 | 4,437 | |||||||||||||
| Less: Comprehensive income (loss) attributable to noncontrolling interests | 39 | 48 | 77 | 32 | |||||||||||||
| Total Comprehensive Income Attributable to Shareowners of The Coca-Cola Company | $ | 4,534 | $ | 1,457 | $ | 8,225 | $ | 4,405 |
Refer to Notes to Consolidated Financial Statements.
THE COCA-COLA COMPANY AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS
(In millions except par value)
| June 27, 2025 | December 31, 2024 | |||||||
| ASSETS | ||||||||
| Current Assets | ||||||||
| Cash and cash equivalents | $ | 9,590 | $ | 10,828 | ||||
| Short-term investments | 2,658 | 2,020 | ||||||
| Total Cash, Cash Equivalents and Short-Term Investments | 12,248 | 12,848 | ||||||
| Marketable securities | 2,049 | 1,723 | ||||||
| Trade accounts receivable, less allowances of $503 and $506, respectively | 4,168 | 3,569 | ||||||
| Inventories | 5,082 | 4,728 | ||||||
| Prepaid expenses and other current assets | 3,062 | 3,129 | ||||||
| Total Current Assets | 26,609 | 25,997 | ||||||
| Equity method investments | 19,379 | 18,087 | ||||||
| Deferred income tax assets | 1,325 | 1,319 | ||||||
| Property, plant and equipment, less accumulated depreciation of $10,081 and $9,570, respectively | 10,784 | 10,303 | ||||||
| Trademarks with indefinite lives | 13,615 | 13,301 | ||||||
| Goodwill | 18,663 | 18,139 | ||||||
| Other noncurrent assets | 13,958 | 13,403 | ||||||
| Total Assets | $ | 104,333 | $ | 100,549 | ||||
| LIABILITIES AND EQUITY | ||||||||
| Current Liabilities | ||||||||
| Accounts payable and accrued expenses | $ | 17,030 | $ | 21,715 | ||||
| Loans and notes payable | 4,379 | 1,499 | ||||||
| Current maturities of long-term debt | 91 | 648 | ||||||
| Accrued income taxes | 444 | 1,387 | ||||||
| Total Current Liabilities | 21,944 | 25,249 | ||||||
| Long-term debt | 44,976 | 42,375 | ||||||
| Other noncurrent liabilities | 4,856 | 4,084 | ||||||
| Deferred income tax liabilities | 2,375 | 2,469 | ||||||
| The Coca-Cola Company Shareowners’ Equity | ||||||||
| Common stock, $0.25 par value; authorized — 11,200 shares; issued — 7,040 shares | 1,760 | 1,760 | ||||||
| Capital surplus | 19,970 | 19,801 | ||||||
| Reinvested earnings | 78,803 | 76,054 | ||||||
| Accumulated other comprehensive income (loss) | (15,758) | (16,843) | ||||||
| Treasury stock, at cost — 2,736 and 2,738 shares, respectively | (56,190) | (55,916) | ||||||
| Equity Attributable to Shareowners of The Coca-Cola Company | 28,585 | 24,856 | ||||||
| Equity attributable to noncontrolling interests | 1,597 | 1,516 | ||||||
| Total Equity | 30,182 | 26,372 | ||||||
| Total Liabilities and Equity | $ | 104,333 | $ | 100,549 |
Refer to Notes to Consolidated Financial Statements.
THE COCA-COLA COMPANY AND SUBSIDIARIES
CONSOLIDATED STATEMENTS OF CASH FLOWS
(In millions)
| Six Months Ended | ||||||||
| June 27, 2025 | June 28, 2024 | |||||||
| Operating Activities | ||||||||
| Consolidated net income | $ | 7,138 | $ | 5,586 | ||||
| Adjustments to reconcile consolidated net income to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 546 | 531 | ||||||
| Stock-based compensation expense | 130 | 140 | ||||||
| Deferred income taxes | 459 | (202) | ||||||
| Equity (income) loss — net of dividends | (387) | (274) | ||||||
| Foreign currency adjustments | 111 | (87) | ||||||
| Significant (gains) losses — net | (433) | (1,398) | ||||||
| Other operating charges | 38 | 2,867 | ||||||
| Other items | 238 | (66) | ||||||
| Net change in operating assets and liabilities | (9,231) | (2,984) | ||||||
| Net Cash Provided by (Used in) Operating Activities | (1,391) | 4,113 | ||||||
| Investing Activities | ||||||||
| Purchases of investments | (2,865) | (3,827) | ||||||
| Proceeds from disposals of investments | 2,201 | 2,662 | ||||||
| Acquisitions of businesses, equity method investments and nonmarketable securities | (179) | (25) | ||||||
| Proceeds from disposals of businesses, equity method investments and nonmarketable securities | 973 | 2,907 | ||||||
| Purchases of property, plant and equipment | (751) | (792) | ||||||
| Proceeds from disposals of property, plant and equipment | 13 | 21 | ||||||
| Collateral (paid) received associated with hedging activities — net | 206 | (76) | ||||||
| Other investing activities | 124 | 127 | ||||||
| Net Cash Provided by (Used in) Investing Activities | (278) | 997 | ||||||
| Financing Activities | ||||||||
| Issuances of loans, notes payable and long-term debt | 5,320 | 6,832 | ||||||
| Payments of loans, notes payable and long-term debt | (2,630) | (4,734) | ||||||
| Issuances of stock | 223 | 437 | ||||||
| Purchases of stock for treasury | (472) | (874) | ||||||
| Dividends | (2,283) | (2,184) | ||||||
| Other financing activities | (106) | (9) | ||||||
| Net Cash Provided by (Used in) Financing Activities | 52 | (532) | ||||||
| Effect of Exchange Rate Changes on Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | 332 | (357) | ||||||
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents | ||||||||
| Net increase (decrease) in cash, cash equivalents, restricted cash and restricted cash equivalents during the period | (1,285) | 4,221 | ||||||
| Cash, cash equivalents, restricted cash and restricted cash equivalents at beginning of period | 11,488 | 9,692 | ||||||
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents at End of Period | 10,203 | 13,913 | ||||||
| Less: Restricted cash and restricted cash equivalents at end of period | 613 | 205 | ||||||
| Cash and Cash Equivalents at End of Period | $ | 9,590 | $ | 13,708 |
Refer to Notes to Consolidated Financial Statements.
THE COCA-COLA COMPANY AND SUBSIDIARIES
NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
NOTE 1: SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES
Basis of Presentation
The accompanying unaudited consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States (“U.S. GAAP”) for interim financial information and with the instructions to Form 10-Q and Rule 10-01 of Regulation S-X. They do not include all information and notes required by U.S. GAAP for complete financial statements. However, except as disclosed herein, there has been no material change in the information disclosed in the Notes to Consolidated Financial Statements included in the Annual Report on Form 10-K of The Coca-Cola Company for the year ended December 31, 2024.
When used in these notes, the terms “The Coca-Cola Company,” “Company,” “we,” “us” and “our” mean The Coca-Cola Company and all entities included in our consolidated financial statements. In the opinion of management, all adjustments (including normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and six months ended June 27, 2025 are not necessarily indicative of the results that may be expected for the year ending December 31, 2025. Sales of our ready-to-drink beverages are somewhat seasonal, with the second and third calendar quarters typically accounting for the highest sales volumes. The volume of sales in the beverage business may be affected by weather conditions.
Each of our quarterly reporting periods, other than the fourth quarter, ends on the Friday closest to the last day of the corresponding quarterly calendar period. The second quarter of 2025 and the second quarter of 2024 ended on June 27, 2025 and June 28, 2024, respectively. Our fourth quarter and our fiscal year end on December 31 regardless of the day of the week on which December 31 falls.
Advertising Costs
The Company’s accounting policy related to advertising costs for annual reporting purposes is to expense production costs of print, radio, television and other advertisements as of the first date the advertisements take place. All other marketing expenditures are expensed in the annual period in which the expenditure is incurred.
For quarterly reporting purposes, we allocate our estimated full year marketing expenditures that benefit multiple quarters to each of those quarters. We use the proportion of each quarter’s actual unit case volume to the estimated full year unit case volume as the basis for the allocation. This methodology results in our marketing expenditures being recognized at a standard rate per unit case. At the end of each quarter, we review our estimated full year unit case volume and our estimated full year marketing expenditures that benefit multiple quarters in order to evaluate if a change in estimate is necessary. The impact of any change in the full year estimate is recognized in the quarter in which the change in estimate occurs. Our full year marketing expenditures are not impacted by this interim accounting policy.
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents
We classify time deposits and other investments that are highly liquid and have maturities of three months or less at the date of purchase as cash equivalents or restricted cash equivalents, as applicable. Restricted cash and restricted cash equivalents generally consist of amounts held by our captive insurance companies, which are included in the line item other noncurrent assets in our consolidated balance sheet, and when applicable, cash and cash equivalents related to assets held for sale are included in the line item prepaid expenses and other current assets in our consolidated balance sheet. We manage our exposure to counterparty credit risk through specific minimum credit standards, diversification of counterparties and procedures to monitor our concentrations of credit risk. Refer to Note 4 for additional information on our captive insurance companies.
The following tables provide a summary of cash, cash equivalents, restricted cash and restricted cash equivalents that constitute the total amounts shown in our consolidated statements of cash flows (in millions):
| June 27, 2025 | December 31, 2024 | ||||||||||
| Cash and cash equivalents | $ | 9,590 | $ | 10,828 | |||||||
| Restricted cash and restricted cash equivalents | 613 | 660 | |||||||||
| Cash, cash equivalents, restricted cash and restricted cash equivalents | $ | 10,203 | $ | 11,488 |
| June 28, 2024 | December 31, 2023 | ||||||||||
| Cash and cash equivalents | $ | 13,708 | $ | 9,366 | |||||||
| Restricted cash and restricted cash equivalents | 205 | 326 | |||||||||
| Cash, cash equivalents, restricted cash and restricted cash equivalents | $ | 13,913 | $ | 9,692 |
NOTE 2: ACQUISITIONS AND DIVESTITURES
Acquisitions
Our Company’s acquisitions of businesses, equity method investments and nonmarketable securities totaled $179 million during the six months ended June 27, 2025, which included $148 million of investments in alternative energy limited partnerships. Refer to Note 15 for additional information on these investments. Our Company’s acquisitions of businesses, equity method investments and nonmarketable securities totaled $25 million during the six months ended June 28, 2024.
Divestitures
Proceeds from disposals of businesses, equity method investments and nonmarketable securities during the six months ended June 27, 2025 totaled $973 million. In March 2025, the Company sold a portion of its ownership interest in Coca-Cola Europacific Partners plc (“CCEP”), an equity method investee, for which we received cash proceeds of $741 million and recognized a net gain of $331 million. In May 2025, the Company refranchised its bottling operations in certain territories in India that were held for sale as of December 31, 2024, for which we received net cash proceeds of $218 million and recognized a net gain of $102 million.
Proceeds from disposals of businesses, equity method investments and nonmarketable securities during the six months ended June 28, 2024 totaled $2,907 million. The Company refranchised its bottling operations in certain territories in India in January and February 2024, for which we received net cash proceeds of $476 million and recognized a net gain of $290 million. In February 2024, the Company refranchised its bottling operations in the Philippines to CCEP and a local business partner, for which we received net cash proceeds of $1,656 million and recognized a net gain of $599 million. We also sold our ownership interest in an equity method investee in Thailand, for which we received net cash proceeds of $728 million and recognized a net gain of $516 million. Additionally, the Company refranchised its bottling operations in Bangladesh to Coca-Cola İçecek A.Ş., an equity method investee, for which we received net cash proceeds of $27 million and a note receivable of $29 million and recognized a net loss of $18 million, primarily due to the related reversal of cumulative translation adjustments. During the six months ended June 27, 2025, the Company recognized an additional loss of $14 million related to post-closing adjustments and a corresponding reduction in the outstanding note receivable balance.
These gains and losses were recorded in the line item other income (loss) — net in our consolidated statements of income.
NOTE 3: NET OPERATING REVENUES
The following tables present net operating revenues disaggregated between the United States and International and further by line of business (in millions):
| United States | International | Total | |||||||||
| Three Months Ended June 27, 2025 | |||||||||||
| Concentrate operations | $ | 2,268 | $ | 6,021 | $ | 8,289 | |||||
| Finished product operations | 2,667 | 1,579 | 4,246 | ||||||||
| Total | $ | 4,935 | $ | 7,600 | $ | 12,535 | |||||
| Three Months Ended June 28, 2024 | |||||||||||
| Concentrate operations | $ | 2,278 | $ | 5,216 | $ | 7,494 | |||||
| Finished product operations | 2,462 | 2,407 | 4,869 | ||||||||
| Total | $ | 4,740 | $ | 7,623 | $ | 12,363 |
| United States | International | Total | |||||||||
| Six Months Ended June 27, 2025 | |||||||||||
| Concentrate operations | $ | 4,195 | $ | 11,277 | $ | 15,472 | |||||
| Finished product operations | 4,993 | 3,199 | 8,192 | ||||||||
| Total | $ | 9,188 | $ | 14,476 | $ | 23,664 | |||||
| Six Months Ended June 28, 2024 | |||||||||||
| Concentrate operations | $ | 4,403 | $ | 9,746 | $ | 14,149 | |||||
| Finished product operations | 4,455 | 5,059 | 9,514 | ||||||||
| Total | $ | 8,858 | $ | 14,805 | $ | 23,663 |
Refer to Note 17 for disclosures of net operating revenues by operating segment and Corporate.
NOTE 4: INVESTMENTS
Equity Securities
The carrying values of our equity securities were included in the following line items in our consolidated balance sheets (in millions):
| Fair Value with Changes Recognized in Income | Measurement Alternative — No Readily Determinable Fair Value | |||||||
| June 27, 2025 | ||||||||
| Marketable securities | $ | 443 | $ | — | ||||
| Other noncurrent assets | 1,828 | 44 | ||||||
| Total equity securities | $ | 2,271 | $ | 44 | ||||
| December 31, 2024 | ||||||||
| Marketable securities | $ | 418 | $ | — | ||||
| Other noncurrent assets | 1,616 | 40 | ||||||
| Total equity securities | $ | 2,034 | $ | 40 |
The calculation of net unrealized gains and losses recognized during the period related to equity securities still held at the end of the period is as follows (in millions):
| Three Months Ended | ||||||||
| June 27, 2025 | June 28, 2024 | |||||||
| Net gains (losses) recognized during the period related to equity securities | $ | 165 | $ | 52 | ||||
| Less: Net gains (losses) recognized during the period related to equity securities sold during the period | (6) | 4 | ||||||
| Net unrealized gains (losses) recognized during the period related to equity securities still held at the end of the period | $ | 171 | $ | 48 | ||||
| Six Months Ended | ||||||||
| June 27, 2025 | June 28, 2024 | |||||||
| Net gains (losses) recognized during the period related to equity securities | $ | 150 | $ | 235 | ||||
| Less: Net gains (losses) recognized during the period related to equity securities sold during the period | 11 | 21 | ||||||
| Net unrealized gains (losses) recognized during the period related to equity securities still held at the end of the period | $ | 139 | $ | 214 | ||||
Debt Securities
Our debt securities consisted of the following (in millions):
| Gross Unrealized | Estimated Fair Value | |||||||||||||
| Cost | Gains | Losses | ||||||||||||
| June 27, 2025 | ||||||||||||||
| Trading securities | $ | 48 | $ | 1 | $ | — | $ | 49 | ||||||
| Available-for-sale securities | 1,988 | 21 | (86) | 1,923 | ||||||||||
| Total debt securities | $ | 2,036 | $ | 22 | $ | (86) | $ | 1,972 | ||||||
| December 31, 2024 | ||||||||||||||
| Trading securities | $ | 45 | $ | 1 | $ | (1) | $ | 45 | ||||||
| Available-for-sale securities | 1,728 | 21 | (118) | 1,631 | ||||||||||
| Total debt securities | $ | 1,773 | $ | 22 | $ | (119) | $ | 1,676 |
The carrying values of our debt securities were included in the following line items in our consolidated balance sheets (in millions):
| June 27, 2025 | December 31, 2024 | ||||||||||||||||
| Trading Securities | Available-for-Sale Securities | Trading Securities | Available-for-Sale Securities | ||||||||||||||
| Marketable securities | $ | 49 | $ | 1,557 | $ | 45 | $ | 1,260 | |||||||||
| Other noncurrent assets | — | 366 | — | 371 | |||||||||||||
| Total debt securities | $ | 49 | $ | 1,923 | $ | 45 | $ | 1,631 |
The contractual maturities of these available-for-sale debt securities as of June 27, 2025 were as follows (in millions):
| Cost | Estimated Fair Value | ||||||||||||||||
| Within 1 year | $ | 406 | $ | 406 | |||||||||||||
| After 1 year through 5 years | 1,365 | 1,311 | |||||||||||||||
| After 5 years through 10 years | 40 | 46 | |||||||||||||||
| After 10 years | 177 | 160 | |||||||||||||||
| Total | $ | 1,988 | $ | 1,923 |
The Company expects that actual maturities may differ from the contractual maturities above because borrowers have the right to call or prepay certain obligations.
The sale and/or maturity of available-for-sale debt securities resulted in the following realized activity (in millions):
| Three Months Ended | Six Months Ended | ||||||||||||||||
| June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | ||||||||||||||
| Gross gains | $ | 2 | $ | 4 | $ | 3 | $ | 5 | |||||||||
| Gross losses | (2) | (2) | (4) | (9) | |||||||||||||
| Proceeds | 70 | 57 | 207 | 440 |
Captive Insurance Companies
In accordance with local insurance regulations, our consolidated captive insurance companies are required to meet and maintain minimum solvency capital requirements. The Company elected to invest a majority of its solvency capital in a portfolio of marketable equity and debt securities. These securities are included in the disclosures above. The Company uses one of our consolidated captive insurance companies to reinsure group annuity insurance contracts that cover the obligations of certain of our European and Canadian pension plans. This captive’s solvency capital funds included total equity and debt securities of $2,076 million and $1,883 million as of June 27, 2025 and December 31, 2024, respectively, which were classified in the line item other noncurrent assets in our consolidated balance sheets because the assets were not available to satisfy our current obligations.
NOTE 5: INVENTORIES
Inventories consisted of the following (in millions):
| June 27, 2025 | December 31, 2024 | |||||||
| Raw materials and packaging | $ | 3,049 | $ | 2,794 | ||||
| Finished goods | 1,608 | 1,524 | ||||||
| Other | 425 | 410 | ||||||
| Total inventories | $ | 5,082 | $ | 4,728 |
NOTE 6: HEDGING TRANSACTIONS AND DERIVATIVE FINANCIAL INSTRUMENTS
The following table presents the fair values of the Company’s derivative instruments that were designated and qualified as part of a hedging relationship (in millions):
| Fair Value1,2 | |||||||||||
| Derivatives Designated as Hedging Instruments | Financial Statement Line Item Impacted1 | June 27, 2025 | December 31, 2024 | ||||||||
| Assets: | |||||||||||
| Foreign currency contracts | Prepaid expenses and other current assets | $ | 66 | $ | 311 | ||||||
| Foreign currency contracts | Other noncurrent assets | 10 | 82 | ||||||||
| Commodity contracts | Prepaid expenses and other current assets | — | 2 | ||||||||
| Interest rate contracts | Other noncurrent assets | 120 | 27 | ||||||||
| Total assets | $ | 196 | $ | 422 | |||||||
| Liabilities: | |||||||||||
| Foreign currency contracts | Accounts payable and accrued expenses | $ | 324 | $ | 14 | ||||||
| Foreign currency contracts | Other noncurrent liabilities | 111 | 39 | ||||||||
| Commodity contracts | Accounts payable and accrued expenses | 7 | — | ||||||||
| Interest rate contracts | Other noncurrent liabilities | 767 | 922 | ||||||||
| Total liabilities | $ | 1,209 | $ | 975 |
1All of the Company’s derivative instruments are carried at fair value in our consolidated balance sheets after considering the impact of legally enforceable master netting agreements and cash collateral held or placed with the same counterparties, as applicable. Current disclosure requirements mandate that derivatives must also be disclosed without reflecting the impact of master netting agreements and cash collateral. Refer to Note 16 for the net presentation of the Company’s derivative instruments.
2Refer to Note 16 for additional information related to the estimated fair value.
The following table presents the fair values of the Company’s derivative instruments that were not designated as hedging instruments (in millions):
| Fair Value1,2 | |||||||||||
| Derivatives Not Designated as Hedging Instruments | Financial Statement Line Item Impacted1 | June 27, 2025 | December 31, 2024 | ||||||||
| Assets: | |||||||||||
| Foreign currency contracts | Prepaid expenses and other current assets | $ | 82 | $ | 152 | ||||||
| Foreign currency contracts | Other noncurrent assets | 32 | 8 | ||||||||
| Commodity contracts | Prepaid expenses and other current assets | 4 | 7 | ||||||||
| Commodity contracts | Other noncurrent assets | 2 | — | ||||||||
| Other derivative instruments | Prepaid expenses and other current assets | 4 | — | ||||||||
| Total assets | $ | 124 | $ | 167 | |||||||
| Liabilities: | |||||||||||
| Foreign currency contracts | Accounts payable and accrued expenses | $ | 144 | $ | 86 | ||||||
| Foreign currency contracts | Other noncurrent liabilities | 8 | 12 | ||||||||
| Commodity contracts | Accounts payable and accrued expenses | 27 | 40 | ||||||||
| Commodity contracts | Other noncurrent liabilities | 2 | — | ||||||||
| Other derivative instruments | Accounts payable and accrued expenses | — | 6 | ||||||||
| Total liabilities | $ | 181 | $ | 144 |
1All of the Company’s derivative instruments are carried at fair value in our consolidated balance sheets after considering the impact of legally enforceable master netting agreements and cash collateral held or placed with the same counterparties, as applicable. Current disclosure requirements mandate that derivatives must also be disclosed without reflecting the impact of master netting agreements and cash collateral. Refer to Note 16 for the net presentation of the Company’s derivative instruments.
2Refer to Note 16 for additional information related to the estimated fair value.
Credit Risk Associated with Derivatives
We have established strict counterparty credit guidelines and enter into transactions only with financial institutions of investment grade or better. We monitor counterparty exposures regularly and review any downgrade in credit rating immediately. If a downgrade in the credit rating of a counterparty were to occur, we have provisions requiring collateral for substantially all of our transactions. To mitigate pre-settlement risk, minimum credit standards become more stringent as the duration of the derivative financial instrument increases. In addition, the Company’s master netting agreements reduce credit risk by permitting the Company to net settle for transactions with the same counterparty. To minimize the concentration of credit risk, we enter into derivative transactions with a portfolio of financial institutions. Furthermore, for certain derivative financial instruments, the Company has agreements with counterparties that require collateral to be exchanged based on changes in the fair value of the instruments. The Company classifies collateral payments and receipts as investing cash flows when the collateral account is in an asset position and as financing cash flows when the collateral account is in a liability position. As a result of these factors, we consider the risk of counterparty default to be minimal.
Cash Flow Hedging Strategy
The Company uses cash flow hedges to minimize the variability in cash flows of assets or liabilities or forecasted transactions caused by fluctuations in foreign currency exchange rates, commodity prices or interest rates. The changes in the fair values of derivatives designated as cash flow hedges are recorded in accumulated other comprehensive income (loss) (“AOCI”) and are reclassified into the line item in our consolidated statement of income in which the hedged items are recorded in the same period the hedged items affect earnings. The changes in the fair values of hedges that are determined to be ineffective are immediately reclassified from AOCI into earnings. The maximum length of time for which the Company hedges its exposure to the variability in future cash flows is typically three years.
The Company maintains a foreign currency cash flow hedging program to reduce the risk that our U.S. dollar net cash inflows from sales outside the United States and U.S. dollar net cash outflows from procurement activities will be adversely affected by fluctuations in foreign currency exchange rates. We enter into forward contracts and purchase foreign currency options and collars (principally euro, British pound and Japanese yen) to hedge certain portions of forecasted cash flows denominated in foreign currencies. When the U.S. dollar strengthens against the foreign currencies, the decline in the present value of future foreign currency cash flows is partially offset by gains in the fair value of the derivative instruments. Conversely, when the U.S. dollar weakens, the increase in the present value of future foreign currency cash flows is partially offset by losses in the fair value of the derivative instruments. The total notional values of derivatives that were designated and qualified for the
Company’s foreign currency cash flow hedging program were $11,831 million and $9,206 million as of June 27, 2025 and December 31, 2024, respectively.
The Company uses cross-currency swaps to hedge the changes in cash flows of certain of its foreign currency denominated debt and other monetary assets or liabilities due to fluctuations in foreign currency exchange rates. For this hedging program, the Company recognizes in earnings each period the changes in carrying values of these foreign currency denominated assets and liabilities due to fluctuations in exchange rates. The changes in fair values of the cross-currency swap derivatives are recorded in AOCI with an immediate reclassification into earnings for the changes in fair values attributable to fluctuations in foreign currency exchange rates. The total notional value of derivatives that were designated as cash flow hedges for the Company’s foreign currency denominated assets and liabilities was $557 million as of both June 27, 2025 and December 31, 2024.
The Company has entered into commodity futures contracts and other derivative instruments on various commodities to mitigate the price risk associated with forecasted purchases of materials used in our manufacturing process. These derivative instruments were designated as part of the Company’s commodity cash flow hedging program. The objective of this hedging program is to reduce the variability of cash flows associated with future purchases of certain commodities. The total notional values of derivatives that were designated and qualified for this program were $65 million and $58 million as of June 27, 2025 and December 31, 2024, respectively.
Our Company monitors our mix of short-term debt and long-term debt regularly. We manage our risk related to interest rate fluctuations through the use of derivative financial instruments. From time to time, the Company has entered into interest rate swap agreements and has designated these instruments as part of the Company’s interest rate cash flow hedging program. The objective of this hedging program is to mitigate the risk of adverse changes in benchmark interest rates on the Company’s future interest payments. The total notional value of derivatives that were designated and qualified for this program was $1,300 million as of June 27, 2025. There were no derivatives that were designated as part of the Company’s interest rate cash flow hedging program as of December 31, 2024.
The following tables present the pretax impact that changes in the fair values of derivatives designated as cash flow hedges had on other comprehensive income (“OCI”), AOCI and earnings (in millions):
| Gain (Loss) Recognized in OCI | Financial Statement Line Item Impacted | Gain (Loss) Reclassified from AOCI into Income | ||||||||||||
| Three Months Ended June 27, 2025 | ||||||||||||||
| Foreign currency contracts | $ | (501) | Net operating revenues | $ | (69) | |||||||||
| Foreign currency contracts | (11) | Cost of goods sold | 1 | |||||||||||
| Foreign currency contracts | — | Interest expense | (1) | |||||||||||
| Foreign currency contracts | 41 | Other income (loss) — net | 44 | |||||||||||
| Commodity contracts | (13) | Cost of goods sold | (5) | |||||||||||
| Interest rate contracts | (1) | Interest expense | — | |||||||||||
| Total | $ | (485) | $ | (30) | ||||||||||
| Three Months Ended June 28, 2024 | ||||||||||||||
| Foreign currency contracts | $ | 160 | Net operating revenues | $ | (1) | |||||||||
| Foreign currency contracts | 9 | Cost of goods sold | 6 | |||||||||||
| Foreign currency contracts | — | Interest expense | (1) | |||||||||||
| Foreign currency contracts | (9) | Other income (loss) — net | 2 | |||||||||||
| Commodity contracts | (3) | Cost of goods sold | (2) | |||||||||||
| Interest rate contracts | 1 | Interest expense | — | |||||||||||
| Total | $ | 158 | $ | 4 |
| Gain (Loss) Recognized in OCI | Financial Statement Line Item Impacted | Gain (Loss) Reclassified from AOCI into Income | ||||||||||||
| Six Months Ended June 27, 2025 | ||||||||||||||
| Foreign currency contracts | $ | (770) | Net operating revenues | $ | (28) | |||||||||
| Foreign currency contracts | (18) | Cost of goods sold | 4 | |||||||||||
| Foreign currency contracts | — | Interest expense | (2) | |||||||||||
| Foreign currency contracts | 37 | Other income (loss) — net | 68 | |||||||||||
| Commodity contracts | (10) | Cost of goods sold | (2) | |||||||||||
| Interest rate contracts | (1) | Interest expense | (1) | |||||||||||
| Total | $ | (762) | $ | 39 | ||||||||||
| Six Months Ended June 28, 2024 | ||||||||||||||
| Foreign currency contracts | $ | 208 | Net operating revenues | $ | (18) | |||||||||
| Foreign currency contracts | 20 | Cost of goods sold | 9 | |||||||||||
| Foreign currency contracts | — | Interest expense | (2) | |||||||||||
| Foreign currency contracts | (24) | Other income (loss) — net | (26) | |||||||||||
| Commodity contracts | (2) | Cost of goods sold | (3) | |||||||||||
| Interest rate contracts | 2 | Interest expense | — | |||||||||||
| Total | $ | 204 | $ | (40) |
As of June 27, 2025, the Company estimates that it will reclassify into earnings during the next 12 months net losses of $339 million from the pretax amount recorded in AOCI as the anticipated cash flows occur.
Fair Value Hedging Strategy
The Company uses interest rate swap agreements designated as fair value hedges to minimize exposure to changes in the fair value of fixed-rate debt that result from fluctuations in benchmark interest rates. The Company also uses cross-currency interest rate swaps to hedge the changes in the fair value of foreign currency denominated debt relating to fluctuations in foreign currency exchange rates and benchmark interest rates. The changes in the fair values of derivatives designated as fair value hedges and the offsetting changes in the fair values of the hedged items are recognized in earnings. As a result, any difference is reflected in earnings as ineffectiveness. When a derivative is no longer designated as a fair value hedge for any reason, including termination and maturity, the remaining unamortized difference between the carrying value of the hedged item at that time and the face value of the hedged item is amortized to earnings over the remaining life of the hedged item, or immediately if the hedged item has matured or has been extinguished. The total notional values of derivatives that were designated and qualified as fair value hedges of this type were $13,655 million and $12,628 million as of June 27, 2025 and December 31, 2024, respectively.
The following tables summarize the pretax impact that changes in the fair values of derivatives designated as fair value hedges had on earnings (in millions):
| Hedging Instruments and Hedged Items | Financial Statement Line Item Impacted | Gain (Loss) Recognized in Income | |||||||||
| Three Months Ended | |||||||||||
| June 27, 2025 | June 28, 2024 | ||||||||||
| Interest rate contracts | Interest expense | $ | 168 | $ | (19) | ||||||
| Fixed-rate debt | Interest expense | (170) | 20 | ||||||||
| Net impact of fair value hedging instruments | $ | (2) | $ | 1 |
| Hedging Instruments and Hedged Items | Financial Statement Line Item Impacted | Gain (Loss) Recognized in Income | |||||||||
| Six Months Ended | |||||||||||
| June 27, 2025 | June 28, 2024 | ||||||||||
| Interest rate contracts | Interest expense | $ | 248 | $ | (164) | ||||||
| Fixed-rate debt | Interest expense | (246) | 167 | ||||||||
| Net impact of fair value hedging instruments | $ | 2 | $ | 3 |
The following table summarizes the amounts recorded in our consolidated balance sheets related to hedged items in fair value hedging relationships (in millions):
| Cumulative Amount of Fair Value Hedging Adjustments1 | ||||||||||||||||||||||||||
| Carrying Values of Hedged Items | Included in the Carrying Values of Hedged Items | Remaining for Which Hedge Accounting Has Been Discontinued | ||||||||||||||||||||||||
| Balance Sheet Location of Hedged Items | June 27, 2025 | December 31, 2024 | June 27, 2025 | December 31, 2024 | June 27, 2025 | December 31, 2024 | ||||||||||||||||||||
| Long-term debt | $ | 13,083 | $ | 11,824 | $ | (755) | $ | (915) | $ | 114 | $ | 130 |
1Cumulative amount of fair value hedging adjustments does not include changes due to foreign currency exchange rate fluctuations.
Hedges of Net Investments in Foreign Operations Strategy
The Company uses forward contracts and a portion of its foreign currency denominated debt, a non-derivative financial instrument, to protect the value of our net investments in a number of foreign operations. During the three months ended June 27, 2025, the Company changed its policy for assessing the effectiveness for derivative financial instruments designated as net investment hedges to include only the changes in fair value attributable to changes in foreign currency spot rates. The changes in the fair values of the effective portion of the derivative financial instruments are recognized in net foreign currency translation adjustments, a component of AOCI, to offset the changes in the values of the net investments being hedged. The initial value, and subsequent changes in fair value of the excluded component, are amortized into earnings over the life of the hedging instrument. For non-derivative financial instruments that are designated and qualify as hedges of net investments in foreign operations, the changes in the carrying values of the designated portions of the non-derivative financial instruments due to fluctuations in foreign currency exchange rates are recorded in net foreign currency translation adjustments. Any ineffective portions of net investment hedges are reclassified from AOCI into earnings during the period of change.
The following table summarizes the notional values and pretax impact of changes in the fair values of instruments designated as net investment hedges (in millions):
| Notional Values | Gain (Loss) Recognized in OCI | |||||||||||||||||||||||||
| as of | Three Months Ended | Six Months Ended | ||||||||||||||||||||||||
| June 27, 2025 | December 31, 2024 | June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | |||||||||||||||||||||
| Foreign currency contracts | $ | 1,067 | $ | 59 | $ | — | $ | 22 | $ | (1) | $ | 24 | ||||||||||||||
| Foreign currency denominated debt | 14,965 | 13,221 | (1,139) | 85 | (1,744) | 357 | ||||||||||||||||||||
| Total | $ | 16,032 | $ | 13,280 | $ | (1,139) | $ | 107 | $ | (1,745) | $ | 381 |
The Company reclassified a gain of $3 million related to net investment hedges from AOCI into earnings during the six months ended June 28, 2024. The Company did not reclassify any gains or losses during the three and six months ended June 27, 2025, nor the three months ended June 28, 2024. The cash inflows and outflows associated with the Company’s derivative contracts designated as net investment hedges are classified in the line item other investing activities in our consolidated statement of cash flows.
Economic (Non-Designated) Hedging Strategy
In addition to derivative instruments that have been designated and qualify for hedge accounting, the Company also uses certain derivatives as economic hedges of foreign currency, interest rate and commodity exposure. Although these derivatives were not designated and/or did not qualify for hedge accounting, they are effective economic hedges. The changes in the fair values of economic hedges are immediately recognized in earnings.
The Company uses foreign currency economic hedges to offset the earnings impact that fluctuations in foreign currency exchange rates have on certain monetary assets and liabilities denominated in nonfunctional currencies. The changes in the fair values of economic hedges used to offset those monetary assets and liabilities are immediately recognized in earnings in the line item other income (loss) — net in our consolidated statement of income. In addition, we use foreign currency economic hedges to minimize the variability in cash flows associated with fluctuations in foreign currency exchange rates, including those related to certain acquisition and divestiture activities. The changes in the fair values of economic hedges used to offset the variability in U.S. dollar net cash flows are immediately recognized in earnings in the line items net operating revenues, cost of goods sold or other income (loss) — net in our consolidated statement of income, as applicable. The total notional values of derivatives related to our foreign currency economic hedges were $13,455 million and $8,620 million as of June 27, 2025 and December 31, 2024, respectively.
The Company also uses certain derivatives as economic hedges to mitigate the price risk associated with the purchase of materials used in the manufacturing process and vehicle fuel. The changes in the fair values of these economic hedges are
immediately recognized in earnings in the line items net operating revenues, cost of goods sold, or selling, general and administrative expenses in our consolidated statement of income, as applicable. The total notional values of derivatives related to our economic hedges of this type were $643 million and $328 million as of June 27, 2025 and December 31, 2024, respectively.
The following tables present the pretax impact that changes in the fair values of derivatives not designated as hedging instruments had on earnings (in millions):
| Derivatives Not Designated as Hedging Instruments | Financial Statement Line Item Impacted | Gain (Loss) Recognized in Income | |||||||||
| Three Months Ended | |||||||||||
| June 27, 2025 | June 28, 2024 | ||||||||||
| Foreign currency contracts | Net operating revenues | $ | (111) | $ | 58 | ||||||
| Foreign currency contracts | Cost of goods sold | 58 | (22) | ||||||||
| Foreign currency contracts | Other income (loss) — net | 67 | (96) | ||||||||
| Commodity contracts | Cost of goods sold | (10) | (49) | ||||||||
| Other derivative instruments | Selling, general and administrative expenses | 11 | 6 | ||||||||
| Total | $ | 15 | $ | (103) |
| Derivatives Not Designated as Hedging Instruments | Financial Statement Line Item Impacted | Gain (Loss) Recognized in Income | |||||||||
| Six Months Ended | |||||||||||
| June 27, 2025 | June 28, 2024 | ||||||||||
| Foreign currency contracts | Net operating revenues | $ | (182) | $ | 119 | ||||||
| Foreign currency contracts | Cost of goods sold | 79 | (8) | ||||||||
| Foreign currency contracts | Other income (loss) — net | 96 | (58) | ||||||||
| Commodity contracts | Cost of goods sold | (6) | (68) | ||||||||
| Other derivative instruments | Selling, general and administrative expenses | 12 | 12 | ||||||||
| Total | $ | (1) | $ | (3) |
NOTE 7: SUPPLY CHAIN FINANCE PROGRAM
Our current payment terms with the majority of our suppliers are 120 days. Certain financial institutions offer a voluntary supply chain finance (“SCF”) program, which enables our suppliers, at their sole discretion, to sell their receivables from the Company to these financial institutions on a non-recourse basis at a rate that leverages our credit rating and thus may be more beneficial to them. The SCF program is available to suppliers of goods and services included in cost of goods sold and selling, general and administrative expenses in our consolidated statement of income. The Company and our suppliers agree on contractual terms for the goods and services we procure, including prices, quantities and payment terms, regardless of whether the supplier elects to participate in the SCF program. The suppliers sell goods or services, as applicable, to the Company and issue the associated invoices to the Company based on the agreed-upon contractual terms. Then, if they are participating in the SCF program, our suppliers sell their invoices to the financial institutions. Our suppliers’ voluntary participation in the SCF program has no bearing on our payment terms. No guarantees are provided by the Company or any of our subsidiaries under the SCF program. We have no economic interest in a supplier’s decision to participate in the SCF program, and we have no direct financial relationship with the financial institutions, as it relates to the SCF program. Accordingly, amounts due to our suppliers that elected to participate in the SCF program are included in the line item accounts payable and accrued expenses in our consolidated balance sheet. All activity related to amounts due to suppliers that elected to participate in the SCF program is reflected within the operating activities section of our consolidated statement of cash flows. As of June 27, 2025 and December 31, 2024, the amount of obligations outstanding that the Company has confirmed as valid to the financial institutions under the SCF program was $1,325 million and $1,330 million, respectively.
NOTE 8: DEBT AND BORROWING ARRANGEMENTS
Loans and notes payable consist primarily of commercial paper issued in the United States. As of June 27, 2025 and December 31, 2024, we had $4,040 million and $1,139 million, respectively, in outstanding commercial paper borrowings.
During the six months ended June 27, 2025, our bottling operations in Africa refinanced $569 million of current maturities of long-term debt into long-term debt.
NOTE 9: COMMITMENTS AND CONTINGENCIES
Guarantees
As of June 27, 2025, we were contingently liable for guarantees of indebtedness owed by third parties of $810 million, of which $61 million was related to variable interest entities. Our guarantees are primarily related to third-party customers, bottlers and vendors and have arisen through the normal course of business. These guarantees have various terms, and none of these guarantees is individually significant. These amounts represent the maximum potential future payments that we could be required to make under the guarantees. However, management has concluded that the likelihood of any significant amounts being paid by our Company under these guarantees is remote.
Concentrations of Credit Risk
We believe our exposure to concentrations of credit risk is limited due to the diverse geographic areas covered by our operations.
Legal Contingencies
The Company is involved in various legal proceedings. We establish reserves for specific legal proceedings when we determine that the likelihood of an unfavorable outcome is probable and the amount of loss can be reasonably estimated. Management has also identified certain other legal matters where we believe an unfavorable outcome is reasonably possible and/or for which no estimate of possible losses can be made. Management believes that the total liabilities of the Company that may arise as a result of currently pending legal proceedings (excluding tax audit claims) will not have a material adverse effect on the Company taken as a whole.
Tax Audits
The Company is involved in various tax matters, with respect to some of which the outcome is uncertain. These uncertain tax matters may result in the assessment of additional taxes.
On September 17, 2015, the Company received a Statutory Notice of Deficiency (“Notice”) from the United States Internal Revenue Service (“IRS”) seeking approximately $3.3 billion of additional federal income tax for years 2007 through 2009. In the Notice, the IRS stated its intent to reallocate over $9 billion of income to the U.S. parent company from certain of its foreign affiliates that the U.S. parent company licensed to manufacture, distribute, sell, market and promote its products in certain non-U.S. markets.
The Notice concerned the Company’s transfer pricing between its U.S. parent company and certain of its foreign affiliates. IRS rules governing transfer pricing require arm’s-length pricing of transactions between related parties such as the Company’s U.S. parent and its foreign affiliates.
To resolve the same transfer pricing issue for the tax years 1987 through 1995, the Company and the IRS had agreed in 1996 on an arm’s-length methodology for determining the amount of U.S. taxable income that the U.S. parent company would report as compensation from its foreign licensees. The Company and the IRS memorialized this accord in a closing agreement resolving that dispute (“Closing Agreement”). The Closing Agreement provided that, absent a change in material facts or circumstances or relevant federal tax law, in calculating the Company’s income taxes going forward, the Company would not be assessed penalties by the IRS for using the agreed-upon tax calculation methodology that the Company and the IRS agreed would be used for the 1987 through 1995 tax years.
The IRS audited and confirmed the Company’s compliance with the agreed-upon Closing Agreement methodology in five successive audit cycles for tax years 1996 through 2006.
The September 17, 2015 Notice from the IRS retroactively rejected the previously agreed-upon methodology for the 2007 through 2009 tax years in favor of an entirely different methodology, without prior notice to the Company. Using the new tax calculation methodology, the IRS reallocated over $9 billion of income to the U.S. parent company from its foreign licensees for tax years 2007 through 2009. Consistent with the Closing Agreement, the IRS did not assert penalties, and it has yet to do so.
The IRS designated the Company’s matter for litigation on October 15, 2015. Litigation designation is an IRS determination that forecloses to a company any and all alternative means for resolution of a tax dispute. As a result of the IRS’ designation of the Company’s matter for litigation, the Company was forced to either accept the IRS’ newly imposed tax assessment and pay the full amount of the asserted tax or litigate the matter in the federal courts. The matter remains subject to the IRS’ litigation designation, preventing the Company from any attempt to settle or otherwise mutually resolve the matter with the IRS.
The Company consequently initiated litigation by filing a petition in the U.S. Tax Court (“Tax Court”) in December 2015, challenging the tax adjustments enumerated in the Notice.
Prior to trial, the IRS increased its transfer pricing adjustment by $385 million, resulting in an additional tax adjustment of $135 million. The Company obtained a summary judgment in its favor on a different matter related to Mexican foreign tax credits, which thereafter effectively reduced the IRS’ potential tax adjustment by $138 million.
The trial was held in the Tax Court from March through May 2018, and final post-trial briefs were filed and exchanged in April 2019.
On November 18, 2020, the Tax Court issued an opinion (“Opinion”) in which it predominantly sided with the IRS but agreed with the Company that dividends previously paid by the foreign licensees to the U.S. parent company in reliance upon the Closing Agreement should continue to be allowed to offset royalties, including those that would become payable to the Company in accordance with the Opinion. On November 8, 2023, the Tax Court issued a supplemental opinion (together with the original Tax Court opinion, “Opinions”), siding with the IRS in concluding both that certain U.S. tax regulations (known as the blocked-income regulations) that address the effect of certain Brazilian legal restrictions on royalty payments by the Company’s licensee in Brazil apply to the Company’s operations and that the Tax Court opinion in 3M Co. & Subs. v. Commissioner (February 9, 2023) controlled as to the validity of those regulations.
The Company believes that the IRS and the Tax Court misinterpreted and misapplied the applicable regulations in reallocating income earned by the Company’s foreign licensees to increase the Company’s U.S. tax. Moreover, the Company believes that the retroactive imposition of such tax liability using a calculation methodology different from that previously agreed upon by the IRS and the Company, and audited by the IRS for over a decade, is unconstitutional. The Company intends to assert its claims on appeal and vigorously defend its positions. In addition, for its litigation with the IRS and for purposes of its appeal of the Tax Court decision, the Company continues to evaluate the implications of several significant administrative law cases recently decided by the U.S. Supreme Court, most notably Loper Bright v. Raimondo, which overruled Chevron U.S.A., Inc. v. NRDC (“Chevron case”). Since 1984, the Chevron case had required that courts defer to agency interpretations of statutes and agency action. In Ohio v. EPA and Garland v. Cargill, two of the recent decisions, the U.S. Supreme Court demonstrated how courts are to rule on agency interpretations and actions without the deference previously required by the Chevron case*.*
On August 2, 2024, the Tax Court entered a decision reflecting additional federal income tax of $2.7 billion for the 2007 through 2009 tax years. With applicable interest, the total liability for the 2007 through 2009 tax years resulting from the Tax Court’s decision is $6.0 billion, for which the IRS issued the Company invoices on September 3, 2024. The Company paid those invoices (“IRS Tax Litigation Deposit”) on September 10, 2024, which stopped interest from accruing on the additional tax due for the 2007 through 2009 tax years. That amount, plus interest earned, would be refunded in full or in part if the Company’s tax positions are ultimately sustained on appeal. For the three and six months ended June 27, 2025, the Company recorded net interest income of $54 million and $107 million, respectively, related to this tax payment in the line item income taxes in our consolidated statements of income, in accordance with our accounting policy. The payment of the IRS invoices and the related accrued interest were recorded in the line item other noncurrent assets in our consolidated balance sheets as of June 27, 2025 and December 31, 2024. On October 22, 2024, the Company appealed the Tax Court’s decision to the U.S. Court of Appeals for the Eleventh Circuit. The Company filed its principal appellate brief with the U.S. Court of Appeals for the Eleventh Circuit on March 12, 2025. The IRS filed its appellate brief on July 7, 2025.
In determining the amount of tax reserve to be recorded as of December 31, 2020, the Company completed the required two-step evaluation process prescribed by Accounting Standards Codification 740, Accounting for Income Taxes. In doing so, we consulted with outside advisors, and we reviewed and considered relevant laws, rules, and regulations, including, but not limited to, the Opinions and relevant caselaw. We also considered our intention to vigorously defend our positions and assert our various well-founded legal claims via every available avenue of appeal. We concluded, based on the technical and legal merits of the Company’s tax positions, that it is more likely than not the Company’s tax positions will ultimately be sustained on appeal. In addition, we considered a number of alternative transfer pricing methodologies, including the methodology asserted by the IRS and affirmed in the Opinions (“Tax Court Methodology”), that could be applied by the courts upon final resolution of the litigation. Based on the required probability analysis, we determined the methodologies we believe the federal courts could ultimately order to be used in calculating the Company’s tax. As a result of this analysis, we recorded a tax reserve of $438 million during the year ended December 31, 2020 related to the application of the resulting methodologies as well as the different tax treatment applicable to dividends originally paid to the U.S. parent company by its foreign licensees, in reliance upon the Closing Agreement, that would be recharacterized as royalties in accordance with the Opinions and the Company’s analysis.
The Company’s conclusion that it is more likely than not the Company’s tax positions will ultimately be sustained on appeal is unchanged as of June 27, 2025. However, based on the required probability analysis and the accrual of interest through the current reporting period, we updated our tax reserve as of June 27, 2025 to $493 million.
While the Company strongly disagrees with the IRS’ positions and the portions of the Opinions affirming such positions, it is possible that some portion or all of the adjustments proposed by the IRS and sustained by the Tax Court could ultimately be upheld. In that event, the Company would not receive a refund of the applicable portion or all of the $6.0 billion it paid in
response to the IRS invoices issued in September 2024 and the related accrued interest receivable of $241 million as of June 27, 2025. Additionally, the Company would likely be subject to significant additional liabilities for subsequent years, which could have a material adverse impact on the Company’s financial position, results of operations and cash flows.
The Company calculated the potential impact of applying the Tax Court Methodology to reallocate income from foreign licensees potentially covered within the scope of the Opinions for the 2010 through 2024 tax years, assuming such methodology were to be ultimately upheld by the courts, and the IRS were to decide to apply that methodology to subsequent years, with consent of the federal courts. This impact would include taxes and interest accrued through December 31, 2024. The calculations incorporated the estimated impact of correlative adjustments to the previously accrued transition tax payable under the 2017 Tax Cuts and Jobs Act. The Company estimates that the potential aggregate remaining incremental tax and interest liability for the tax years 2010 through 2024 could be approximately $12 billion as of December 31, 2024. Additional income tax and interest on any unpaid potential liabilities for the 2010 through 2024 tax years would continue to accrue until the time any such potential liability, or portion thereof, were to be paid. The Company estimates the impact of the continued application of the Tax Court Methodology for the three and six months ended June 27, 2025 would increase the potential aggregate incremental tax and interest liability by approximately $400 million and $800 million, respectively. We currently project the continued application of the Tax Court Methodology in 2025, assuming similar facts and circumstances as of December 31, 2024, would result in an incremental annual tax liability that would increase the Company’s effective tax rate by approximately 3.5%.
Risk Management Programs
The Company has numerous global insurance programs in place to help protect the Company from the risk of loss. In general, we are self-insured for large portions of many different types of claims; however, we do use commercial insurance above our self-insured retentions to reduce the Company’s risk of catastrophic loss. Our reserves for the Company’s self-insured losses are estimated using actuarial methods and assumptions of the insurance industry, adjusted for our specific expectations based on our claims history. Our self-insurance reserves totaled $169 million and $168 million as of June 27, 2025 and December 31, 2024, respectively.
NOTE 10: OTHER COMPREHENSIVE INCOME
AOCI attributable to shareowners of The Coca-Cola Company is separately presented in our consolidated balance sheet as a component of shareowners’ equity, which also includes our proportionate share of equity method investees’ AOCI. OCI attributable to noncontrolling interests is allocated to, and included in, our consolidated balance sheet as part of the line item equity attributable to noncontrolling interests.
AOCI attributable to shareowners of The Coca-Cola Company consisted of the following, net of tax (in millions):
| June 27, 2025 | December 31, 2024 | |||||||
| Net foreign currency translation adjustments | $ | (13,967) | $ | (15,610) | ||||
| Accumulated net gains (losses) on derivatives | (485) | 116 | ||||||
| Unrealized net gains (losses) on available-for-sale debt securities | (41) | (64) | ||||||
| Adjustments to pension and other postretirement benefit liabilities | (1,265) | (1,285) | ||||||
| Accumulated other comprehensive income (loss) | $ | (15,758) | $ | (16,843) |
The following table summarizes the allocation of total comprehensive income between shareowners of The Coca-Cola Company and noncontrolling interests (in millions):
| Six Months Ended June 27, 2025 | |||||||||||
| Shareowners of The Coca-Cola Company | Noncontrolling Interests | Total | |||||||||
| Consolidated net income | $ | 7,140 | $ | (2) | $ | 7,138 | |||||
| Other comprehensive income: | |||||||||||
| Net foreign currency translation adjustments | 1,643 | 79 | 1,722 | ||||||||
| Net gains (losses) on derivatives1 | (601) | — | (601) | ||||||||
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | 23 | — | 23 | ||||||||
| Net change in pension and other postretirement benefit liabilities | 20 | — | 20 | ||||||||
| Total comprehensive income (loss) | $ | 8,225 | $ | 77 | $ | 8,302 |
1Refer to Note 6 for additional information related to the net gains or losses on derivative instruments.
2Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities.
The following tables present OCI attributable to shareowners of The Coca-Cola Company, including our proportionate share of equity method investees’ OCI (in millions):
| Three Months Ended June 27, 2025 | Before-Tax Amount | Income Tax | After-Tax Amount | ||||||||
| Foreign currency translation adjustments: | |||||||||||
| Translation adjustments arising during the period | $ | 95 | $ | (84) | $ | 11 | |||||
| Gains (losses) on intra-entity transactions that are of a long-term investment nature | 1,901 | — | 1,901 | ||||||||
| Gains (losses) on net investment hedges arising during the period1 | (1,139) | 284 | (855) | ||||||||
| Net foreign currency translation adjustments | $ | 857 | $ | 200 | $ | 1,057 | |||||
| Derivatives: | |||||||||||
| Gains (losses) arising during the period | $ | (485) | $ | 118 | $ | (367) | |||||
| Reclassification adjustments recognized in net income | 30 | (7) | 23 | ||||||||
| Net gains (losses) on derivatives1 | $ | (455) | $ | 111 | $ | (344) | |||||
| Available-for-sale debt securities: | |||||||||||
| Unrealized gains (losses) arising during the period | $ | 16 | $ | (6) | $ | 10 | |||||
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ | 16 | $ | (6) | $ | 10 | |||||
| Pension and other postretirement benefit liabilities: | |||||||||||
| Net pension and other postretirement benefit liabilities arising during the period | $ | (22) | $ | 4 | $ | (18) | |||||
| Reclassification adjustments recognized in net income | 26 | (7) | 19 | ||||||||
| Net change in pension and other postretirement benefit liabilities | $ | 4 | $ | (3) | $ | 1 | |||||
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ | 422 | $ | 302 | $ | 724 |
1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments.
2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities.
| Six Months Ended June 27, 2025 | Before-Tax Amount | Income Tax | After-Tax Amount | ||||||||
| Foreign currency translation adjustments: | |||||||||||
| Translation adjustments arising during the period | $ | 103 | $ | (93) | $ | 10 | |||||
| Reclassification adjustments recognized in net income | 34 | (2) | 32 | ||||||||
| Gains (losses) on intra-entity transactions that are of a long-term investment nature | 2,911 | — | 2,911 | ||||||||
| Gains (losses) on net investment hedges arising during the period1 | (1,745) | 435 | (1,310) | ||||||||
| Net foreign currency translation adjustments | $ | 1,303 | $ | 340 | $ | 1,643 | |||||
| Derivatives: | |||||||||||
| Gains (losses) arising during the period | $ | (759) | $ | 187 | $ | (572) | |||||
| Reclassification adjustments recognized in net income | (39) | 10 | (29) | ||||||||
| Net gains (losses) on derivatives1 | $ | (798) | $ | 197 | $ | (601) | |||||
| Available-for-sale debt securities: | |||||||||||
| Unrealized gains (losses) arising during the period | $ | 32 | $ | (10) | $ | 22 | |||||
| Reclassification adjustments recognized in net income | 1 | — | 1 | ||||||||
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ | 33 | $ | (10) | $ | 23 | |||||
| Pension and other postretirement benefit liabilities: | |||||||||||
| Net pension and other postretirement benefit liabilities arising during the period | $ | (39) | $ | 14 | $ | (25) | |||||
| Reclassification adjustments recognized in net income | 59 | (14) | 45 | ||||||||
| Net change in pension and other postretirement benefit liabilities | $ | 20 | $ | — | $ | 20 | |||||
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ | 558 | $ | 527 | $ | 1,085 |
1 Refer to Note 6 for additional information related to the net gains or losses on derivative instruments.
2 Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities.
| Three Months Ended June 28, 2024 | Before-Tax Amount | Income Tax | After-Tax Amount | ||||||||
| Foreign currency translation adjustments: | |||||||||||
| Translation adjustments arising during the period | $ | (1,109) | $ | 127 | $ | (982) | |||||
| Gains (losses) on intra-entity transactions that are of a long-term investment nature | (170) | — | (170) | ||||||||
| Gains (losses) on net investment hedges arising during the period1 | 107 | (27) | 80 | ||||||||
| Net foreign currency translation adjustments | $ | (1,172) | $ | 100 | $ | (1,072) | |||||
| Derivatives: | |||||||||||
| Gains (losses) arising during the period | $ | 156 | $ | (35) | $ | 121 | |||||
| Reclassification adjustments recognized in net income | (4) | 1 | (3) | ||||||||
| Net gains (losses) on derivatives1 | $ | 152 | $ | (34) | $ | 118 | |||||
| Available-for-sale debt securities: | |||||||||||
| Unrealized gains (losses) arising during the period | $ | (38) | $ | 13 | $ | (25) | |||||
| Reclassification adjustments recognized in net income | (2) | — | (2) | ||||||||
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ | (40) | $ | 13 | $ | (27) | |||||
| Pension and other postretirement benefit liabilities: | |||||||||||
| Net pension and other postretirement benefit liabilities arising during the period | $ | 4 | $ | 6 | $ | 10 | |||||
| Reclassification adjustments recognized in net income | 23 | (6) | 17 | ||||||||
| Net change in pension and other postretirement benefit liabilities | $ | 27 | $ | — | $ | 27 | |||||
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ | (1,033) | $ | 79 | $ | (954) |
1Refer to Note 6 for additional information related to the net gains or losses on derivative instruments.
2Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities.
| Six Months Ended June 28, 2024 | Before-Tax Amount | Income Tax | After-Tax Amount | ||||||||
| Foreign currency translation adjustments: | |||||||||||
| Translation adjustments arising during the period | $ | (1,143) | $ | 92 | $ | (1,051) | |||||
| Reclassification adjustments recognized in net income | 103 | — | 103 | ||||||||
| Gains (losses) on intra-entity transactions that are of a long-term investment nature | (688) | — | (688) | ||||||||
| Gains (losses) on net investment hedges arising during the period1 | 381 | (96) | 285 | ||||||||
| Net foreign currency translation adjustments | $ | (1,347) | $ | (4) | $ | (1,351) | |||||
| Derivatives: | |||||||||||
| Gains (losses) arising during the period | $ | 183 | $ | (46) | $ | 137 | |||||
| Reclassification adjustments recognized in net income | 40 | (10) | 30 | ||||||||
| Net gains (losses) on derivatives1 | $ | 223 | $ | (56) | $ | 167 | |||||
| Available-for-sale debt securities: | |||||||||||
| Unrealized gains (losses) arising during the period | $ | (38) | $ | 13 | $ | (25) | |||||
| Reclassification adjustments recognized in net income | 4 | (1) | 3 | ||||||||
| Net change in unrealized gains (losses) on available-for-sale debt securities2 | $ | (34) | $ | 12 | $ | (22) | |||||
| Pension and other postretirement benefit liabilities: | |||||||||||
| Net pension and other postretirement benefit liabilities arising during the period | $ | (9) | $ | (2) | $ | (11) | |||||
| Reclassification adjustments recognized in net income | 45 | (11) | 34 | ||||||||
| Net change in pension and other postretirement benefit liabilities | $ | 36 | $ | (13) | $ | 23 | |||||
| Other comprehensive income (loss) attributable to shareowners of The Coca-Cola Company | $ | (1,122) | $ | (61) | $ | (1,183) |
1Refer to Note 6 for additional information related to the net gains or losses on derivative instruments.
2Refer to Note 4 for additional information related to the net unrealized gains or losses on available-for-sale debt securities.
The following table presents the amounts and line items in our consolidated statements of income where adjustments reclassified from AOCI into income were recorded (in millions):
| Amount Reclassified from AOCI into Income | ||||||||||||||
| Description of AOCI Component | Financial Statement Line Item Impacted | Three Months Ended June 27, 2025 | Six Months Ended June 27, 2025 | |||||||||||
| Foreign currency translation adjustments: | ||||||||||||||
| Divestitures1 | Other income (loss) — net | $ | — | $ | 34 | |||||||||
| Income before income taxes | — | 34 | ||||||||||||
| Income taxes | — | (2) | ||||||||||||
| Consolidated net income | $ | — | $ | 32 | ||||||||||
| Derivatives: | ||||||||||||||
| Foreign currency contracts | Net operating revenues | $ | 69 | $ | 28 | |||||||||
| Foreign currency and commodity contracts | Cost of goods sold | 4 | (2) | |||||||||||
| Foreign currency and interest rate contracts | Interest expense | 1 | 3 | |||||||||||
| Foreign currency contracts | Other income (loss) — net | (44) | (68) | |||||||||||
| Income before income taxes | 30 | (39) | ||||||||||||
| Income taxes | (7) | 10 | ||||||||||||
| Consolidated net income | $ | 23 | $ | (29) | ||||||||||
| Available-for-sale debt securities: | ||||||||||||||
| Sale of debt securities | Other income (loss) — net | $ | — | $ | 1 | |||||||||
| Income before income taxes | — | 1 | ||||||||||||
| Income taxes | — | — | ||||||||||||
| Consolidated net income | $ | — | $ | 1 | ||||||||||
| Pension and other postretirement benefit liabilities: | ||||||||||||||
| Divestitures1 | Other income (loss) — net | $ | — | $ | (2) | |||||||||
| Curtailment loss (gain) | Other income (loss) — net | — | 11 | |||||||||||
| Amortization of net actuarial loss (gain) | Other income (loss) — net | 26 | 51 | |||||||||||
| Amortization of prior service cost (credit) | Other income (loss) — net | — | (1) | |||||||||||
| Income before income taxes | 26 | 59 | ||||||||||||
| Income taxes | (7) | (14) | ||||||||||||
| Consolidated net income | $ | 19 | $ | 45 |
1 Related to the sale of a portion of our ownership interest in CCEP. Refer to Note 2.
NOTE 11: CHANGES IN EQUITY
The following tables provide a reconciliation of the beginning and ending carrying amounts of total equity, equity attributable to shareowners of The Coca-Cola Company and equity attributable to noncontrolling interests (in millions):
| Shareowners of The Coca-Cola Company | ||||||||||||||||||||||||||
| Three Months Ended June 27, 2025 | Common Shares Outstanding | Total | Reinvested Earnings | Accumulated Other Comprehensive Income (Loss) | Common Stock | Capital Surplus | Treasury Stock | Non-controlling Interests | ||||||||||||||||||
| March 28, 2025 | 4,304 | $ | 27,754 | $ | 77,189 | $ | (16,482) | $ | 1,760 | $ | 19,873 | $ | (56,138) | $ | 1,552 | |||||||||||
| Comprehensive income (loss) | — | 4,573 | 3,810 | 724 | — | — | — | 39 | ||||||||||||||||||
| Dividends paid/payable to shareowners of The Coca-Cola Company ($0.51 per share) | — | (2,196) | (2,196) | — | — | — | — | — | ||||||||||||||||||
| Dividends paid to noncontrolling interests | — | (7) | — | — | — | — | — | (7) | ||||||||||||||||||
| Contributions by noncontrolling interests | — | 13 | — | — | — | — | — | 13 | ||||||||||||||||||
| Purchases of treasury stock | (1) | (81) | — | — | — | — | (81) | — | ||||||||||||||||||
| Impact related to stock-based compensation plans | 1 | 126 | — | — | — | 97 | 29 | — | ||||||||||||||||||
| June 27, 2025 | 4,304 | $ | 30,182 | $ | 78,803 | $ | (15,758) | $ | 1,760 | $ | 19,970 | $ | (56,190) | $ | 1,597 |
| Shareowners of The Coca-Cola Company | ||||||||||||||||||||||||||
| Six Months Ended June 27, 2025 | Common Shares Outstanding | Total | Reinvested Earnings | Accumulated Other Comprehensive Income (Loss) | Common Stock | Capital Surplus | Treasury Stock | Non-controlling Interests | ||||||||||||||||||
| December 31, 2024 | 4,302 | $ | 26,372 | $ | 76,054 | $ | (16,843) | $ | 1,760 | $ | 19,801 | $ | (55,916) | $ | 1,516 | |||||||||||
| Comprehensive income (loss) | — | 8,302 | 7,140 | 1,085 | — | — | — | 77 | ||||||||||||||||||
| Dividends paid/payable to shareowners of The Coca-Cola Company ($1.02 per share) | — | (4,391) | (4,391) | — | — | — | — | — | ||||||||||||||||||
| Dividends paid to noncontrolling interests | — | (9) | — | — | — | — | — | (9) | ||||||||||||||||||
| Contributions by noncontrolling interests | — | 13 | — | — | — | — | — | 13 | ||||||||||||||||||
| Purchases of treasury stock | (5) | (360) | — | — | — | — | (360) | — | ||||||||||||||||||
| Impact related to stock-based compensation plans | 7 | 255 | — | — | — | 169 | 86 | — | ||||||||||||||||||
| June 27, 2025 | 4,304 | $ | 30,182 | $ | 78,803 | $ | (15,758) | $ | 1,760 | $ | 19,970 | $ | (56,190) | $ | 1,597 |
| Shareowners of The Coca-Cola Company | ||||||||||||||||||||||||||
| Three Months Ended June 28, 2024 | Common Shares Outstanding | Total | Reinvested Earnings | Accumulated Other Comprehensive Income (Loss) | Common Stock | Capital Surplus | Treasury Stock | Non-controlling Interests | ||||||||||||||||||
| March 29, 2024 | 4,308 | $ | 27,946 | $ | 74,868 | $ | (14,504) | $ | 1,760 | $ | 19,321 | $ | (55,016) | $ | 1,517 | |||||||||||
| Comprehensive income (loss) | — | 1,505 | 2,411 | (954) | — | — | — | 48 | ||||||||||||||||||
| Dividends paid/payable to shareowners of The Coca-Cola Company ($0.485 per share) | — | (2,090) | (2,090) | — | — | — | — | — | ||||||||||||||||||
| Dividends paid to noncontrolling interests | — | (7) | — | — | — | — | — | (7) | ||||||||||||||||||
| Purchases of treasury stock | (3) | (156) | — | — | — | — | (156) | — | ||||||||||||||||||
| Impact related to stock-based compensation plans | 4 | 213 | — | — | — | 147 | 66 | — | ||||||||||||||||||
| June 28, 2024 | 4,309 | $ | 27,411 | $ | 75,189 | $ | (15,458) | $ | 1,760 | $ | 19,468 | $ | (55,106) | $ | 1,558 |
| Shareowners of The Coca-Cola Company | ||||||||||||||||||||||||||
| Six Months Ended June 28, 2024 | Common Shares Outstanding | Total | Reinvested Earnings | Accumulated Other Comprehensive Income (Loss) | Common Stock | Capital Surplus | Treasury Stock | Non-controlling Interests | ||||||||||||||||||
| December 31, 2023 | 4,308 | $ | 27,480 | $ | 73,782 | $ | (14,275) | $ | 1,760 | $ | 19,209 | $ | (54,535) | $ | 1,539 | |||||||||||
| Comprehensive income (loss) | — | 4,437 | 5,588 | (1,183) | — | — | — | 32 | ||||||||||||||||||
| Dividends paid/payable to shareowners of The Coca-Cola Company ($0.97 per share) | — | (4,181) | (4,181) | — | — | — | — | — | ||||||||||||||||||
| Dividends paid to noncontrolling interests | — | (9) | — | — | — | — | — | (9) | ||||||||||||||||||
| Divestitures | — | (4) | — | — | — | — | — | (4) | ||||||||||||||||||
| Purchases of treasury stock | (13) | (777) | — | — | — | — | (777) | — | ||||||||||||||||||
| Impact related to stock-based compensation plans | 14 | 465 | — | — | — | 259 | 206 | — | ||||||||||||||||||
| June 28, 2024 | 4,309 | $ | 27,411 | $ | 75,189 | $ | (15,458) | $ | 1,760 | $ | 19,468 | $ | (55,106) | $ | 1,558 |
On July 22, 2025, we sold a noncontrolling interest in our bottling operations in India to a local partner for approximately $1.4 billion.
NOTE 12: SIGNIFICANT OPERATING AND NONOPERATING ITEMS
Other Operating Charges
During the three months ended June 27, 2025, the Company recorded other operating charges of $71 million. These charges primarily included $31 million related to the impairment of a trademark in Latin America, $28 million related to the Company’s productivity and reinvestment program, $7 million of transaction costs related to the refranchising of our bottling operations in certain territories in India, $4 million for the amortization of noncompete agreements related to the BA Sports Nutrition, LLC (“BodyArmor”) acquisition in 2021 and $2 million related to tax litigation expense.
During the six months ended June 27, 2025, the Company recorded other operating charges of $144 million. These charges consisted of $47 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with our acquisition of fairlife, LLC (“fairlife”) in 2020, which brought the total liability to $6,173 million and was paid in March 2025. Additionally, other operating charges included $39 million related to the Company’s productivity and reinvestment program, $31 million related to the impairment of a trademark in Latin America, $8 million related to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations, $7 million for the amortization of noncompete agreements related to the BodyArmor acquisition, $7 million of transaction costs related to the refranchising of our bottling operations in certain territories in India and $5 million related to tax litigation expense.
During the three months ended June 28, 2024, the Company recorded other operating charges of $1,370 million. These charges consisted of $1,337 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition, $32 million related to the Company’s productivity and reinvestment program and $3 million for the amortization of noncompete agreements related to the BodyArmor acquisition. These charges were partially offset by a net benefit of $2 million related to a revision of management’s estimates for tax litigation expense.
During the six months ended June 28, 2024, the Company recorded other operating charges of $2,943 million. These charges consisted of $2,102 million related to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition, $760 million related to the impairment of our BodyArmor trademark and $68 million related to the Company’s productivity and reinvestment program. In addition, other operating charges included $7 million for transaction costs related to the refranchising of our bottling operations in certain territories in India and $7 million for the amortization of noncompete agreements related to the BodyArmor acquisition. These charges were partially offset by a net benefit of $1 million related to a revision of management’s estimates for tax litigation expense.
Refer to Note 2 for additional information on the refranchising of our bottling operations in certain territories in India. Refer to Note 9 for additional information on the tax litigation. Refer to Note 13 for additional information on the Company’s restructuring initiatives. Refer to Note 16 for additional information on the fairlife acquisition and the impairments. Refer to Note 17 for the impact certain of these charges had on our operating segments and Corporate.
Other Nonoperating Items
Equity Income (Loss) — Net
During the three and six months ended June 27, 2025, the Company recorded net charges of $20 million and $28 million, respectively. During the three and six months ended June 28, 2024, the Company recorded net charges of $24 million and $49 million, respectively. These amounts represent the Company’s proportionate share of significant operating and nonoperating items recorded by certain of our equity method investees.
Other Income (Loss) — Net
During the three months ended June 27, 2025, the Company recognized a net gain of $163 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities, a net gain of $102 million related to the refranchising of our bottling operations in certain territories in India, an other-than-temporary impairment charge of $40 million related to an equity method investee in Latin America and a charge of $28 million related to assets held for sale.
During the six months ended June 27, 2025, the Company recognized a net gain of $331 million related to the sale of a portion of our ownership interest in CCEP, a net gain of $144 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities, and a net gain of $102 million related to the refranchising of our bottling operations in certain territories in India. The Company also recorded other-than-temporary impairment charges of $40 million related to an equity method investee in Latin America and $25 million related to a joint venture in Latin America, as well as a charge of $28 million related to assets held for sale, and charges of $25 million and $11 million for special termination benefits and a curtailment loss, respectively, related to non-U.S. pension activity.
During the three months ended June 28, 2024, the Company recognized a net gain of $50 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities and an other-than-temporary impairment charge of $34 million related to an equity method investee in Latin America.
During the six months ended June 28, 2024, the Company recognized net gains of $599 million and $290 million related to the refranchising of our bottling operations in the Philippines and certain territories in India, respectively. The Company also recognized a net gain of $516 million related to the sale of our ownership interest in an equity method investee in Thailand. Additionally, the Company recognized a net gain of $228 million related to realized and unrealized gains and losses on equity securities and trading debt securities as well as realized gains and losses on available-for-sale debt securities. These gains were partially offset by an other-than-temporary impairment charge of $34 million related to an equity method investee in Latin America and a loss of $7 million related to post-closing adjustments for the refranchising of our bottling operations in Vietnam in 2023.
Refer to Note 2 for additional information on the sale of our ownership interest in CCEP, the sale of our ownership interest in an equity method investee in Thailand and the refranchising of our bottling operations. Refer to Note 4 for additional information on equity and debt securities. Refer to Note 14 for additional information on the non-U.S. pension curtailment and special termination benefits. Refer to Note 16 for additional information on the impairment charges and the assets held for sale.
NOTE 13: RESTRUCTURING
Productivity and Reinvestment Program
In February 2012, the Company announced a productivity and reinvestment program designed to strengthen our brands and reinvest our resources to drive long-term profitable growth. The program was expanded multiple times, with the last expansion occurring in April 2017. While most of the initiatives included in this program were substantially completed by the end of 2024, certain initiatives, which are primarily designed to further simplify and standardize our organization, have been delayed and will be completed during 2025.
During the three and six months ended June 27, 2025, the Company incurred expenses of $28 million and $39 million, respectively, and during the three and six months ended June 28, 2024, incurred expenses of $32 million and $68 million, respectively, related to our productivity and reinvestment program. These expenses primarily included internal and external costs associated with the implementation of the program’s initiatives and were recorded in the line item other operating charges in our consolidated statements of income. Refer to Note 17 for the impact these expenses had on our operating segments and Corporate. The Company has incurred total pretax expenses of $4,465 million related to this program since it commenced.
NOTE 14: PENSION AND OTHER POSTRETIREMENT BENEFIT PLANS
Net periodic benefit cost or income for our pension and other postretirement benefit plans consisted of the following (in millions):
| Pension Plans | Other Postretirement Benefit Plans | ||||||||||||||||
| Three Months Ended | |||||||||||||||||
| June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | ||||||||||||||
| Service cost | $ | 25 | $ | 26 | $ | 1 | $ | 1 | |||||||||
| Interest cost | 74 | 77 | 2 | 5 | |||||||||||||
| Expected return on plan assets1 | (104) | (117) | (1) | (2) | |||||||||||||
| Amortization of prior service cost (credit) | — | 1 | — | (1) | |||||||||||||
| Amortization of net actuarial loss (gain) | 26 | 25 | — | (1) | |||||||||||||
| Net periodic benefit cost (income) | $ | 21 | $ | 12 | $ | 2 | $ | 2 |
1The weighted-average expected long-term rates of return on plan assets used in computing 2025 net periodic benefit cost (income) were 7.00% for pension plans and 6.75% for other postretirement benefit plans.
| Pension Plans | Other Postretirement Benefit Plans | ||||||||||||||||
| Six Months Ended | |||||||||||||||||
| June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | ||||||||||||||
| Service cost | $ | 51 | $ | 53 | $ | 2 | $ | 2 | |||||||||
| Interest cost | 149 | 154 | 5 | 9 | |||||||||||||
| Expected return on plan assets1 | (208) | (235) | (2) | (4) | |||||||||||||
| Amortization of prior service cost (credit) | — | 1 | (1) | (2) | |||||||||||||
| Amortization of net actuarial loss (gain) | 51 | 51 | — | (2) | |||||||||||||
| Curtailment loss (gain)2 | 11 | — | — | — | |||||||||||||
| Special termination benefits2 | 25 | — | — | — | |||||||||||||
| Net periodic benefit cost (income) | $ | 79 | $ | 24 | $ | 4 | $ | 3 |
1The weighted-average expected long-term rates of return on plan assets used in computing 2025 net periodic benefit cost (income) were 7.00% for pension plans and 6.75% for other postretirement benefit plans.
2The curtailment loss and special termination benefits were related to the group annuity purchase (“buy-in”) for a non-U.S. defined benefit plan. The Company intends to convert the buy-in to a buy-out in the future, at which time the insurer would assume full responsibility for the plan obligations.
All of the amounts in the tables above, other than service cost, were recorded in the line item other income (loss) — net in our consolidated statements of income. During the six months ended June 27, 2025, the Company contributed $17 million to our pension trusts, offset by $331 million in transfers of surplus non-U.S. plan assets from pension trusts to general assets of the Company. We anticipate making additional contributions of approximately $12 million during the remainder of 2025. The Company contributed $16 million to our pension trusts, offset by a $44 million transfer of surplus non-U.S. plan assets from pension trusts to general assets of the Company during the six months ended June 28, 2024.
NOTE 15: INCOME TAXES
The Company recorded income taxes of $993 million (20.7% effective tax rate) and $627 million (20.7% effective tax rate) during the three months ended June 27, 2025 and June 28, 2024, respectively. The Company recorded income taxes of $1,715 million (19.4% effective tax rate) and $1,314 million (19.0% effective tax rate) during the six months ended June 27, 2025 and June 28, 2024, respectively.
The Company’s effective tax rates for the three and six months ended June 27, 2025 and June 28, 2024 vary from the statutory U.S. federal tax rate of 21.0%, primarily due to the tax impact of significant operating and nonoperating items, as described in Note 12, along with the tax benefits of having significant earnings generated outside of the United States and significant earnings generated in investments accounted for under the equity method, both of which are generally taxed at rates lower than the statutory U.S. federal tax rate.
The Company’s effective tax rates for the three and six months ended June 27, 2025 included $12 million and $155 million, respectively, of net tax benefits related to various discrete tax items, including net interest income of $54 million and
$107 million, respectively, related to the IRS Tax Litigation Deposit recorded in the line item income taxes in our consolidated statements of income, in accordance with our accounting policy. The Company’s effective tax rate for the six months ended June 27, 2025 also included a tax benefit of $85 million related to a change in the Company’s indefinite reinvestment assertion for certain foreign entities.
The Company’s effective tax rates for the three and six months ended June 28, 2024 included $119 million and $60 million, respectively, of net tax expense related to various discrete tax items, including the resolution of certain foreign tax matters.
During the six months ended June 27, 2025, the Company invested $148 million in limited partnerships that receive tax credits and other tax benefits by constructing, owning and operating alternative energy generation facilities. During the three and six months ended June 27, 2025, the Company received tax credits and other income tax benefits of $146 million and $155 million, respectively, and recognized amortization expense of $135 million and $142 million, respectively, related to all of our investments of this nature. The amount of non-income tax-related activity and other returns related to these investments was not material during the six months ended June 27, 2025. As of June 27, 2025, the carrying value of these investments was $48 million. The Company recorded $123 million of unfunded commitments related to these investments in the line item accounts payable and accrued expenses in our consolidated balance sheets as of June 27, 2025 and December 31, 2024. The Company expects to fulfill these unfunded commitments in 2025.
On November 18, 2020, the Tax Court issued the Opinion regarding the Company’s 2015 litigation with the IRS involving transfer pricing tax adjustments in which it predominantly sided with the IRS. On November 8, 2023, the Tax Court issued a supplemental opinion, siding with the IRS in concluding both that the blocked-income regulations apply to the Company’s operations and that the Tax Court opinion in 3M Co. & Subs. v. Commissioner (February 9, 2023) controlled as to the validity of those regulations. On August 2, 2024, the Tax Court entered a decision reflecting additional federal income tax of $2.7 billion for the 2007 through 2009 tax years. With applicable interest, the total liability for the 2007 through 2009 tax years resulting from the Tax Court’s decision is $6.0 billion. On October 22, 2024, the Company appealed the Tax Court’s decision to the U.S. Court of Appeals for the Eleventh Circuit. The Company filed its principal appellate brief with the U.S. Court of Appeals for the Eleventh Circuit on March 12, 2025. The Company strongly disagrees with the Opinions and intends to vigorously defend its positions. Refer to Note 9.
NOTE 16: FAIR VALUE MEASUREMENTS
Recurring Fair Value Measurements
The following tables summarize assets and liabilities measured at fair value on a recurring basis (in millions):
| June 27, 2025 | Level 1 | Level 2 | Level 3 | Other3 | Netting Adjustment | 4 | Fair Value Measurements | ||||||||||||||||||||||
| Assets: | |||||||||||||||||||||||||||||
| Equity securities with readily determinable values1 | $ | 1,959 | $ | 158 | $ | 30 | $ | 124 | $ | — | $ | 2,271 | |||||||||||||||||
| Debt securities1 | — | 1,972 | — | — | — | 1,972 | |||||||||||||||||||||||
| Derivatives2 | — | 320 | — | — | (307) | 5 | 13 | 7 | |||||||||||||||||||||
| Total assets | $ | 1,959 | $ | 2,450 | $ | 30 | $ | 124 | $ | (307) | $ | 4,256 | |||||||||||||||||
| Liabilities: | |||||||||||||||||||||||||||||
| Derivatives2 | $ | 7 | $ | 1,383 | $ | — | $ | — | $ | (1,006) | 6 | $ | 384 | 7 | |||||||||||||||
| Total liabilities | $ | 7 | $ | 1,383 | $ | — | $ | — | $ | (1,006) | $ | 384 |
1Refer to Note 4 for additional information related to the composition of our equity securities with readily determinable values and debt securities.
2Refer to Note 6 for additional information related to the composition of our derivatives portfolio.
3Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy but are included to reconcile to the amounts presented in Note 4.
4Amounts represent the impact of legally enforceable master netting agreements that allow the Company to settle net positive and negative positions and also cash collateral held or placed with the same counterparties. There were no amounts subject to legally enforceable master netting agreements that management has chosen not to offset or that do not meet the offsetting requirements. Refer to Note 6.
5The Company is obligated to return $14 million in cash collateral it has netted against its derivative position.
6The Company has the right to reclaim $712 million in cash collateral it has netted against its derivative position.
7The Company’s derivative financial instruments were recorded at fair value in our consolidated balance sheet as follows: $13 million in the line item other noncurrent assets and $384 million in the line item other noncurrent liabilities. Refer to Note 6 for additional information related to the composition of our derivatives portfolio.
| December 31, 2024 | Level 1 | Level 2 | Level 3 | Other3 | Netting Adjustment | 4 | Fair Value Measurements | ||||||||||||||||||||||
| Assets: | |||||||||||||||||||||||||||||
| Equity securities with readily determinable values1 | $ | 1,790 | $ | 137 | $ | 13 | $ | 94 | $ | — | $ | 2,034 | |||||||||||||||||
| Debt securities1 | — | 1,676 | — | — | — | 1,676 | |||||||||||||||||||||||
| Derivatives2 | 2 | 587 | — | — | (370) | 6 | 219 | 8 | |||||||||||||||||||||
| Total assets | $ | 1,792 | $ | 2,400 | $ | 13 | $ | 94 | $ | (370) | $ | 3,929 | |||||||||||||||||
| Liabilities: | |||||||||||||||||||||||||||||
| Contingent consideration liability | $ | — | $ | — | $ | 6,126 | 5 | $ | — | $ | — | $ | 6,126 | ||||||||||||||||
| Derivatives2 | — | 1,119 | — | — | (1,097) | 7 | 22 | 8 | |||||||||||||||||||||
| Total liabilities | $ | — | $ | 1,119 | $ | 6,126 | $ | — | $ | (1,097) | $ | 6,148 |
1Refer to Note 4 for additional information related to the composition of our equity securities with readily determinable values and debt securities.
2Refer to Note 6 for additional information related to the composition of our derivatives portfolio.
3Certain investments that are measured at fair value using the net asset value per share (or its equivalent) practical expedient have not been categorized in the fair value hierarchy but are included to reconcile to the amounts presented in Note 4.
4Amounts represent the impact of legally enforceable master netting agreements that allow the Company to settle net positive and negative positions and also cash collateral held or placed with the same counterparties. There were no amounts subject to legally enforceable master netting agreements that management has chosen not to offset or that do not meet the offsetting requirements. Refer to Note 6.
5Represents the fair value of the remaining milestone payment related to our acquisition of fairlife, which is contingent on fairlife achieving certain financial targets through 2024 and is payable in 2025. This milestone payment is based on agreed-upon formulas related to fairlife’s operating results, the resulting value of which is not subject to a ceiling. The fair value was determined using discounted cash flow analyses. We are required to remeasure this liability to fair value quarterly, with any changes in the fair value recorded in income until the final milestone payment is made.
6The Company was obligated to return $12 million in cash collateral it had netted against its derivative position.
7The Company had the right to reclaim $735 million in cash collateral it had netted against its derivative position.
8The Company’s derivative financial instruments were recorded at fair value in our consolidated balance sheet as follows: $102 million in the line item prepaid expenses and other current assets, $117 million in the line item other noncurrent assets and $22 million in the line item other noncurrent liabilities. Refer to Note 6 for additional information related to the composition of our derivatives portfolio.
Gross realized and unrealized gains and losses on Level 3 assets and liabilities, excluding the contingent consideration liability, were not significant for the three and six months ended June 27, 2025 and June 28, 2024.
The Company recognizes transfers between levels within the hierarchy as of the beginning of the reporting period. Gross transfers between levels within the hierarchy were not significant for the three and six months ended June 27, 2025 and June 28, 2024.
Nonrecurring Fair Value Measurements
The gains and losses on assets measured at fair value on a nonrecurring basis are summarized in the following table (in millions):
| Gains (Losses) | ||||||||||||||||||||||||||
| Three Months Ended | Six Months Ended | |||||||||||||||||||||||||
| June 27, 2025 | June 28, 2024 | June 27, 2025 | June 28, 2024 | |||||||||||||||||||||||
| Other-than-temporary impairment charges | $ | (40) | 1 | $ | (34) | 1 | $ | (65) | 1,4 | $ | (34) | 1 | ||||||||||||||
| Impairment of intangible assets | (31) | 2 | — | (31) | 2 | (760) | 5 | |||||||||||||||||||
| Assets held for sale | (28) | 3 | — | (28) | 3 | — | ||||||||||||||||||||
| Total | $ | (99) | $ | (34) | $ | (124) | $ | (794) |
1During the three and six months ended June 27, 2025 and June 28, 2024, the Company recorded other-than-temporary impairment charges of $40 million and $34 million, respectively, related to an equity method investee in Latin America. These impairment charges were derived using Level 3 inputs and were primarily driven by revised projections of future operating results. These charges were recorded in the line item other income (loss) — net in our consolidated statements of income.
2During the three and six months ended June 27, 2025, the Company recorded an asset impairment charge of $31 million related to a trademark in Latin America. This impairment charge was derived using Level 3 inputs and was primarily driven by revised projections of future operating results and changes in macroeconomic conditions. This charge was recorded in the line item other operating charges in our consolidated statements of income. The remaining carrying value of the trademark is $55 million.
3The Company is required to record assets and liabilities that are held for sale at the lower of carrying value or fair value less any costs to sell based on the agreed-upon sale price. During the three and six months ended June 27, 2025, the Company recorded a charge of $28 million in the line item other income (loss) — net in our consolidated statements of income. This charge was due to the write-down of assets held for sale related to the refranchising of certain bottling operations in Ghana. This charge, which was calculated based on Level 3 inputs, primarily impacted the line item property, plant and equipment in our consolidated balance sheet.
4During the six months ended June 27, 2025, the Company recorded an other-than-temporary impairment charge of $25 million related to a joint venture in Latin America. This impairment charge was derived using Level 3 inputs and was due to the joint venture’s restructuring and planned liquidation. This charge was recorded in the line item other income (loss) — net in our consolidated statement of income.
5During the six months ended June 28, 2024, the Company recorded an asset impairment charge of $760 million related to our BodyArmor trademark in North America, which was primarily driven by revised projections of future operating results and higher discount rates resulting from changes in macroeconomic conditions since the acquisition date. The fair value of this trademark was derived using discounted cash flow analyses based on Level 3 inputs. This charge was recorded in the line item other operating charges in our consolidated statement of income. The remaining carrying value of the trademark is $3,400 million.
Other Fair Value Disclosures
The carrying values of cash and cash equivalents, short-term investments, trade accounts receivable, accounts payable and accrued expenses, and loans and notes payable approximate their fair values because of the relatively short-term maturities of these financial instruments. The fair value of our long-term debt is estimated using Level 2 inputs based on quoted prices for those instruments. Where quoted prices are not available, the fair value is estimated using discounted cash flows and market-based expectations for interest rates, credit risk and the contractual terms of the debt instruments. As of June 27, 2025, the carrying value and fair value of our long-term debt, including the current portion, were $45,067 million and $40,184 million, respectively. As of December 31, 2024, the carrying value and fair value of our long-term debt, including the current portion, were $43,023 million and $38,052 million, respectively.
NOTE 17: OPERATING SEGMENTS
Information about our Company’s operations by operating segment and Corporate is as follows (in millions):
| Europe, Middle East & Africa | Latin America | North America | Asia Pacific | Bottling Investments | Corporate | Eliminations | Consolidated | |||||||||||||||||||
| Three Months Ended June 27, 2025 | ||||||||||||||||||||||||||
| Net operating revenues: | ||||||||||||||||||||||||||
| Third party | $ | 3,008 | $ | 1,587 | $ | 5,028 | $ | 1,464 | $ | 1,409 | $ | 39 | $ | — | $ | 12,535 | ||||||||||
| Intersegment | 168 | — | 1 | 108 | 2 | — | (279) | — | ||||||||||||||||||
| Total net operating revenues | 3,176 | 1,587 | 5,029 | 1,572 | 1,411 | 39 | (279) | 12,535 | ||||||||||||||||||
| Cost of goods sold | 895 | 263 | 2,405 | 476 | 1,018 | (64) | (279) | 4,714 | ||||||||||||||||||
| Selling, general and administrative expenses | 956 | 336 | 1,003 | 449 | 334 | 392 | — | 3,470 | ||||||||||||||||||
| Other operating charges | — | 31 | — | — | — | 40 | — | 71 | ||||||||||||||||||
| Operating income (loss) | $ | 1,325 | $ | 957 | $ | 1,621 | $ | 647 | $ | 59 | $ | (329) | $ | — | $ | 4,280 | ||||||||||
| Interest income | 188 | |||||||||||||||||||||||||
| Interest expense | 445 | |||||||||||||||||||||||||
| Equity income (loss) — net | 561 | |||||||||||||||||||||||||
| Other income (loss) — net | 212 | |||||||||||||||||||||||||
| Income before income taxes | $ | 4,796 | ||||||||||||||||||||||||
| Other segment information: | ||||||||||||||||||||||||||
| Capital expenditures | $ | 49 | $ | 1 | $ | 154 | $ | 4 | $ | 119 | $ | 115 | $ | — | $ | 442 | ||||||||||
| Depreciation and amortization | 55 | 8 | 81 | 10 | 76 | 49 | — | 279 | ||||||||||||||||||
| Three Months Ended June 28, 2024 | ||||||||||||||||||||||||||
| Net operating revenues: | ||||||||||||||||||||||||||
| Third party | $ | 2,873 | $ | 1,652 | $ | 4,870 | $ | 1,396 | $ | 1,537 | $ | 35 | $ | — | $ | 12,363 | ||||||||||
| Intersegment | 155 | — | 4 | 126 | 2 | — | (287) | — | ||||||||||||||||||
| Total net operating revenues | 3,028 | 1,652 | 4,874 | 1,522 | 1,539 | 35 | (287) | 12,363 | ||||||||||||||||||
| Cost of goods sold | 816 | 317 | 2,515 | 436 | 1,096 | (81) | (287) | 4,812 | ||||||||||||||||||
| Selling, general and administrative expenses | 930 | 414 | 983 | 440 | 345 | 437 | — | 3,549 | ||||||||||||||||||
| Other operating charges | — | — | — | — | — | 1,370 | — | 1,370 | ||||||||||||||||||
| Operating income (loss) | $ | 1,282 | $ | 921 | $ | 1,376 | $ | 646 | $ | 98 | $ | (1,691) | $ | — | $ | 2,632 | ||||||||||
| Interest income | 275 | |||||||||||||||||||||||||
| Interest expense | 418 | |||||||||||||||||||||||||
| Equity income (loss) — net | 537 | |||||||||||||||||||||||||
| Other income (loss) — net | 2 | |||||||||||||||||||||||||
| Income before income taxes | $ | 3,028 | ||||||||||||||||||||||||
| Other segment information: | ||||||||||||||||||||||||||
| Capital expenditures | $ | 64 | $ | 1 | $ | 116 | $ | 6 | $ | 151 | $ | 84 | $ | — | $ | 422 | ||||||||||
| Depreciation and amortization | 45 | 7 | 82 | 10 | 78 | 47 | — | 269 |
Information about total assets by segment is not disclosed because such information is not regularly provided to, or used by, our Chief Operating Decision Maker.
During the three and six months ended June 27, 2025 and June 28, 2024, our operating segments and Corporate were impacted by acquisition and divestiture activities. Refer to Note 2.
Additionally, during the three months ended June 27, 2025, the results of our operating segments and Corporate were impacted by the following items:
-
Operating income (loss) was reduced by $31 million for Latin America due to the impairment of a trademark. Refer to Note 16.
-
Operating income (loss) was reduced by $28 million for Corporate due to the Company’s productivity and reinvestment program. Refer to Note 13.
-
Operating income (loss) was reduced by $7 million for Corporate due to transaction costs related to the refranchising of our bottling operations in certain territories in India. Refer to Note 2.
-
Operating income (loss) was reduced by $4 million for Corporate due to charges related to our acquisition of BodyArmor. Refer to Note 12.
During the three months ended June 28, 2024, the results of our operating segments and Corporate were impacted by the following items:
-
Operating income (loss) was reduced by $1,337 million for Corporate due to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition. Refer to Note 16.
-
Operating income (loss) was reduced by $32 million for Corporate due to the Company’s productivity and reinvestment program. Refer to Note 13.
-
Operating income (loss) was reduced by $7 million for North America due to the restructuring of our manufacturing operations in the United States.
-
Operating income (loss) was reduced by $3 million for Corporate due to charges related to our acquisition of BodyArmor. Refer to Note 12.
| Europe, Middle East & Africa | Latin America | North America | Asia Pacific | Bottling Investments | Corporate | Eliminations | Consolidated | |||||||||||||||||||
| Six Months Ended June 27, 2025 | ||||||||||||||||||||||||||
| Net operating revenues: | ||||||||||||||||||||||||||
| Third party | $ | 5,489 | $ | 3,064 | $ | 9,387 | $ | 2,789 | $ | 2,870 | $ | 65 | $ | — | $ | 23,664 | ||||||||||
| Intersegment | 344 | — | 3 | 204 | 4 | — | (555) | — | ||||||||||||||||||
| Total net operating revenues | 5,833 | 3,064 | 9,390 | 2,993 | 2,874 | 65 | (555) | 23,664 | ||||||||||||||||||
| Cost of goods sold | 1,654 | 537 | 4,511 | 866 | 2,028 | (164) | (555) | 8,877 | ||||||||||||||||||
| Selling, general and administrative expenses | 1,789 | 635 | 1,917 | 856 | 668 | 839 | — | 6,704 | ||||||||||||||||||
| Other operating charges | — | 31 | — | — | — | 113 | — | 144 | ||||||||||||||||||
| Operating income (loss) | $ | 2,390 | $ | 1,861 | $ | 2,962 | $ | 1,271 | $ | 178 | $ | (723) | $ | — | $ | 7,939 | ||||||||||
| Interest income | 368 | |||||||||||||||||||||||||
| Interest expense | 832 | |||||||||||||||||||||||||
| Equity income (loss) — net | 912 | |||||||||||||||||||||||||
| Other income (loss) — net | 466 | |||||||||||||||||||||||||
| Income before income taxes | $ | 8,853 | ||||||||||||||||||||||||
| Other segment information: | ||||||||||||||||||||||||||
| Capital expenditures | $ | 90 | $ | 1 | $ | 269 | $ | 5 | $ | 224 | $ | 162 | $ | — | $ | 751 | ||||||||||
| Depreciation and amortization | 99 | 15 | 162 | 22 | 152 | 96 | — | 546 | ||||||||||||||||||
| Six Months Ended June 28, 2024 | ||||||||||||||||||||||||||
| Net operating revenues: | ||||||||||||||||||||||||||
| Third party | $ | 5,308 | $ | 3,182 | $ | 9,094 | $ | 2,661 | $ | 3,352 | $ | 66 | $ | — | $ | 23,663 | ||||||||||
| Intersegment | 352 | — | 6 | 342 | 4 | — | (704) | — | ||||||||||||||||||
| Total net operating revenues | 5,660 | 3,182 | 9,100 | 3,003 | 3,356 | 66 | (704) | 23,663 | ||||||||||||||||||
| Cost of goods sold | 1,549 | 566 | 4,625 | 835 | 2,361 | (185) | (704) | 9,047 | ||||||||||||||||||
| Selling, general and administrative expenses | 1,749 | 750 | 1,842 | 865 | 741 | 953 | — | 6,900 | ||||||||||||||||||
| Other operating charges | — | — | 760 | — | — | 2,183 | — | 2,943 | ||||||||||||||||||
| Operating income (loss) | $ | 2,362 | $ | 1,866 | $ | 1,873 | $ | 1,303 | $ | 254 | $ | (2,885) | $ | — | $ | 4,773 | ||||||||||
| Interest income | 521 | |||||||||||||||||||||||||
| Interest expense | 800 | |||||||||||||||||||||||||
| Equity income (loss) — net | 891 | |||||||||||||||||||||||||
| Other income (loss) — net | 1,515 | |||||||||||||||||||||||||
| Income before income taxes | $ | 6,900 | ||||||||||||||||||||||||
| Other segment information: | ||||||||||||||||||||||||||
| Capital expenditures | $ | 102 | $ | 1 | $ | 217 | $ | 10 | $ | 328 | $ | 134 | $ | — | $ | 792 | ||||||||||
| Depreciation and amortization | 90 | 14 | 159 | 21 | 169 | 78 | — | 531 |
During the six months ended June 27, 2025, the results of our operating segments and Corporate were impacted by the following items:
-
Operating income (loss) was reduced by $47 million for Corporate due to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition.
-
Operating income (loss) was reduced by $39 million for Corporate due to the Company’s productivity and reinvestment program. Refer to Note 13.
-
Operating income (loss) was reduced by $31 million for Latin America due to the impairment of a trademark. Refer to Note 16.
-
Operating income (loss) was reduced by $8 million for Corporate due to an indemnification agreement entered into as a part of the refranchising of certain of our bottling operations.
-
Operating income (loss) was reduced by $7 million for Corporate due to charges related to our acquisition of BodyArmor. Refer to Note 12.
-
Operating income (loss) was reduced by $7 million for Corporate due to transaction costs related to the refranchising of our bottling operations in certain territories in India. Refer to Note 2.
During the six months ended June 28, 2024, the results of our operating segments and Corporate were impacted by the following items:
-
Operating income (loss) was reduced by $2,102 million for Corporate due to the remeasurement of our contingent consideration liability to fair value in conjunction with the fairlife acquisition. Refer to Note 16.
-
Operating income (loss) was reduced by $760 million for North America due to the impairment of our BodyArmor trademark. Refer to Note 16.
-
Operating income (loss) was reduced by $68 million for Corporate due to the Company’s productivity and reinvestment program. Refer to Note 13.
-
Operating income (loss) was reduced by $10 million for North America due to the restructuring of our manufacturing operations in the United States.
-
Operating income (loss) was reduced by $7 million for Corporate due to transaction costs related to the refranchising of our bottling operations in certain territories in India. Refer to Note 2.
-
Operating income (loss) was reduced by $7 million for Corporate due to charges related to our acquisition of BodyArmor. Refer to Note 12.
Previous: Cover and table of contents · Next: Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations